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1.  INTRODUCTION 
 
The European Medicines Agency (EMA) established a committee under the name Committee for 
Herbal Medicinal Products (HMPC) for the EU-wide harmonization of the state of knowledge on 
herbal medicinal products and medicinal plants The HMPC has 32 members (one member per 
EU-member state and five co-opted members) and holds six meetings a year at the EMA in 
London. 
One of the legal mandates of the HMPC is the establishment of community monographs on 
herbal substances and herbal preparations according to well-established use and traditional use. 
 
Definition of Well-established use according to Dir. 2001/83 as amended: 
• A defined herbal preparation is in broad medicinal use within the European Union since at 
least 10 years 
• The clinical efficacy in the claimed indication is supported by at least one controlled 
clinical study of good methodological quality 
• There is coherence of the scientific assessment 
• The high degree of scientific interest in the use of the preparation is reflected in the 
published scientific literature 
 
Definition of Traditional use according to Dir. 2001/83 as amended: 
• The herbal preparation or a corresponding product is in medicinal use for at least 30 
years, from this at least 15 years within the European Union 
• Exclusively in indications which do not need medical diagnosis or medical supervision 
• The efficacy must be plausible 
• Route of administration: exclusively for oral use, cutaneous use or inhalation 
 
The use of medicinal plants and products thereof is highly different throughout the European 
Union. Despite existing monograph collections such as ESCOP monographs, pharmacopoeia 
monographs or the Commission E monographs, national barriers remain which is in contrast to 
the main principles of the harmonised markets within the European Union. These barriers should 
be eliminated by the creation of HMPC monographs. 
The creation of Community herbal monographs has the goal of establishing a common basis 
within the EU for the authorisation and registration of herbal medicinal products. A uniform 
scientific basis is to be established.  
Monographs are to be considered by Member States in the assessment of an application for 
authorisation or registration and therefore also represent a service for companies or applicants. 
Provided that a herbal medicinal product complies with the monograph the applicant is not 
obliged to provide the complete literature on safety, efficacy or traditional use. The application 
dossier is more or less restricted to the quality part. 
Unfortunately community monographs are not legally binding at the moment. However, the 
international pressure on member states not accepting monograph conform applications is 
increasing. 
Austria is among the leading member states in the level of acceptance of monographs and also 
intensively involved in the development of such monographs. Austria is among other herbal 
substances responsible for the monographs on Potentilla erecta L. and Syzygium aromaticum L. 
 
This diploma thesis should focus on the search and discussion of scientific literature on Potentilla 
erecta L. and Syzygium aromaticum L. It presents a preliminary draft paper on the well-
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established use (based on article 10A of directive 2004/24/EC) and the traditional use (based on 
article 16D (1) of directive 2004/24/EC) for the Committee for Herbal Medicinal Products of the 
European Medicines Agency (EMA). 
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2. METHODOLOGY 
 
2.1.  LITERATURE SEARCH: 
Period: August 2009 to January 2010 
 
Electronic data search: 
 
Databases: 
• Pubmed (http://www.ncbi.nlm.nih.gov./sites/entrez 
• Toxnet (http://www.toxnet.nlm.nih.gov/) 
• Medline 
 
Keywords: 
Potentilla erecta: Potentilla erecta, Potentilla tormentilla, tormentil, Blutwurz 
Syzygium aromaticum: Syzygium aromaticum, Gewürznelke, Caryophylli flos, Eugenol 
Relevant articles were identified and obtained in full text. 
 
Libraries: 
University Vienna, center of pharmacy; Medical University Vienna, central library 
 
The center of pharmacy of he University of Vienna, the Medical University of Vienna and the 
central library are adequate sources of older handbooks of pharmacy, old pharmacopoeias and old 
handbooks of phytotherapy. These sources are essential for the documentation of the traditional 
use. 
 
 
2.2.  PROCEDURE FOR THE DEVELOPMENT OF COMMUNITY MONOGRAPHS 
The procedure for the establishment of community monographs is defined by standard operations 
procedures (SOPs) from the EMA. The main steps are: 
• Appointment of a rapporteur and a peer-reviewer 
• Literature search by the rapporteur 
• Collection of data concerning authorised medicinal products in the EU member states 
regarding date of authorisation, composition, indication, and posology 
• Assessment of the scientific literature and the period of medicinal use 
• Development of a draft assessment report, a draft monograph and a draft list of references 
• Discussion(s) in the HMPC working party on monographs and lists (MLWP) and revision 
of the documents 
• Adoption of the documents by the HMPC for release for public consultation 
• Consultation phase of three months 
• Interested parties are invited to comment on the draft monograph 
• Rapporteur to collect and assess the comments, documents are modified accordingly; 
rejection of comments has to be justified by the rapporteur 
• Peer review of the documents 
• Adoption of the final documents by the HMPC 
• Publication on the website of the EMA 
 
 8 
At the moment of the compilation of this diploma thesis the draft documents on Tormentillae 
rhizoma are published for consultation. The development of the monograph and assessment 
report on Caryophylli flos and Caryophylli aetheroleum are in the stage before the first discussion 
in the MLWP. 
 
The HMPC provides guidance documents on the evaluation of literature and the preparation of 
the documents. The style and the structure of the documents are defined in templates provided by 
the HMPC. Guidelines and templates are available at the website of the EMA 
(http://www.ema.europa.eu/htms/human/hmpc/index.htm). 
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3.  RESULTS 
 
3.1. POTENTILLA ERECTA (L.) RAEUSCH., RHIZOMA 
 
 
 
London, January 2010 
 Doc. Ref.: EMA/HMPC/5511/2010  
 
 
 
 
COMMITTEE ON HERBAL MEDICINAL PRODUCTS 
(HMPC) 
 
 
 
 
ASSESSMENT REPORT ON 
POTENTILLA ERECTA (L.) Raeusch., RHIZOMA1 
                                                           
1 Botanical name of the plant according to the binomial system (genus, species, variety and author), [comma] the 
plant part in Latin. 
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REGULATORY STATUS OVERVIEW2 
MA: Marketing Authorisation  
TRAD: Traditional Use Registration  
Other TRAD: Other national Traditional systems of registration  
Other: If known, it should be specified or otherwise add ’Not Known’ 
Member State Regulatory Status Comments3 
Austria  MA  TRAD  Other TRAD  Other Specify:   
Belgium  MA  TRAD  Other TRAD  Other Specify:  Food supplements 
Bulgaria  MA  TRAD  Other TRAD  Other Specify:  no response 
Cyprus  MA  TRAD  Other TRAD  Other Specify:  no response 
Czech Republic  MA  TRAD  Other TRAD  Other Specify:  Combinations only 
Denmark  MA  TRAD  Other TRAD  Other Specify:  Food supplements 
Estonia   MA  TRAD  Other TRAD  Other Specify:  No product 
Finland  MA  TRAD  Other TRAD  Other Specify:  no response 
France  MA  TRAD  Other TRAD  Other Specify:  no response 
Germany  MA  TRAD  Other TRAD  Other Specify:  no response 
Greece  MA  TRAD  Other TRAD  Other Specify:  no response 
Hungary  MA  TRAD  Other TRAD  Other Specify:  no response 
Iceland  MA  TRAD  Other TRAD  Other Specify:  no response 
Ireland  MA  TRAD  Other TRAD  Other Specify:  No product 
Italy  MA  TRAD  Other TRAD  Other Specify:  No product 
Latvia  MA  TRAD  Other TRAD  Other Specify:  Combination only 
Liechtenstein  MA  TRAD  Other TRAD  Other Specify:  no response 
Lithuania  MA  TRAD  Other TRAD  Other Specify:   
Luxemburg  MA  TRAD  Other TRAD  Other Specify:  no response 
Malta  MA  TRAD  Other TRAD  Other Specify:  no response 
The Netherlands  MA  TRAD  Other TRAD  Other Specify:  no response 
Norway  MA  TRAD  Other TRAD  Other Specify:  no response 
Poland  MA  TRAD  Other TRAD  Other Specify:   
Portugal  MA  TRAD  Other TRAD  Other Specify:  No product 
Romania  MA  TRAD  Other TRAD  Other Specify:  no response 
Slovak Republic  MA  TRAD  Other TRAD  Other Specify:  No product 
Slovenia  MA  TRAD  Other TRAD  Other Specify:  no response 
Spain  MA  TRAD  Other TRAD  Other Specify:  Tincture (1:10) 
Sweden  MA  TRAD  Other TRAD  Other Specify:  No product 
United Kingdom  MA  TRAD  Other TRAD  Other Specify:  No product 
                                                           
2 This regulatory overview is not legally binding and does not necessarily reflect the legal status of the products in 
the MSs concerned. 
3 Not mandatory field 
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ASSESSMENT REPORT  
 
BASED ON ARTICLE 10A OF DIRECTIVE 2001/83/EC AS AMENDED 
(WELL-ESTABLISHED USE) 
BASED ON ARTICLE 16D(1), ARTICLE 16F AND ARTICLE 16H OF DIRECTIVE 2001/83/EC 
AS AMENDED 
(TRADITIONAL USE) 
 
 
Herbal substance(s) (binomial scientific name of 
the plant, including plant part) 
Potentilla erecta, rhizoma  
Syn: Tormentillae rhizome  
Herbal preparation(s) 
 
A) Comminuted herbal substance 
 
B) Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 70% (v/v) 
 
C) Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 45% v/v 
 
D) Liquid extract (DER 1:1, extraction solvent 
ethanol 25% v/v 
Pharmaceutical forms4 
Comminuted herbal substance as herbal tea for 
oral and oromucosal use. 
Herbal preparations B, C and D in liquid dosage 
forms for oral use. 
Herbal preparation B in liquid dosage forms for 
oromucosal use. 
 
Rapporteur5 Austria 
Assessor(s)6 Reinhard Länger, Birgit Hochenegg 
 
                                                           
4 Pharmaceutical form only according to EDQM standard term 
5 Name of HMPC/MLWP member (not Member State) 
6 To be deleted at publication stage, unless Rapporteur requests to keep the name(s) 
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3.1.1. Introduction 
Description of the herbal substance(s), herbal preparation(s) or combinations thereof 
Herbal substance(s) 7: 
Tormentillae rhizoma consists according to the European Pharmacopoeia of the dried rhizome, freed from 
the roots of Potentilla erecta (L.) Raeusch. It contains not less than 7 per cent of tannins, expressed as 
pyrogallol (C6H6O3, Mr126.1) with reference to the dried herbal substance. 
 
Constituents (according to Hänsel & Sticher 2007, Blaschek at al 2008, Wichtl 2009): 
 
Tannins: 15-22% total tannins; about 70% of them are condensed tannins like catechins (–)- gallo- or (–)-
epigallocatechingallat, the dimeric catechin derivatives [6,6′]-all-trans-bi-(+)-catechin, [4,8]-all-trans-bi-
(+)-catechin (= procyanidin B3), [4,6]-all-trans-bi-(+)-catechin (= procyanidin B6) and [4,8]-2,3-trans-3,4-
cis-bi-(+)-catechin and 3,5% hydrolysed like gallo- and ellagitannine gallic acid, ellagic acid and the main 
component of the hydrolysed tannins is the dimeric agrimoniin, which is contained to about 1% in the 
drug. Further HHDP = hexahydroxy diphenic acid), pedunculagin, laevigatin B und laevigatin F were 
isolated. 
 
Flavonoids: kaempferol, cyanidinglucoside and leucoanthocyanidin and the tannin monomers catechin, 
epicatechin, gallocatechin and epigallocatechin 
 
 
Phenol carboxylic acids: p-coumaric acid, 3,4-dihydroxybenzoic acid, gallic acid, sinapic acid  and caffeic 
acid 
 
Triterpene saponins: quinovic acid, tormentillic acid and tormentosid (glycoside of tormentillic 
acid) 
 
Fatty acids:  in extracts prepared with supercritical CO2 the following constituents are found: 
lauric acid, linoleic acid, linolenic acid, palmitic acid, palmitoleic acid, pentadecanoic acid, 
stearic acid and oleic acid. 
 
Herbal preparation(s): 
The following herbal preparations are in medicinal use in the community for more than 30 years: 
 Herbal preparation References 
A Comminuted herbal substance. 
for preparation of infusions  
for preparation of decoctions (authorized products in Poland, 
on the market for more than 30 years) 
Madaus 1938 
B Tincture (ratio drug : extraction solvent 1:5), extraction 
solvent ethanol 70% (v/v) 
 
 
Monograph in the Czech 
pharmacopoeia since 1970, 
monograph in the Austrian 
pharmacopoeia at least since 
1960, replaced by the monograph 
in Pharm. Eur. 01/2008: 1895. 
C Tincture (ratio drug : extraction solvent 1:5), extraction British Herbal Pharmacopoeia, 
                                                           
6 According to the ‘Procedure for the preparation of Community monographs for traditional herbal medicinal 
products’ (EMEA/HMPC/182320/2005 Rev.2) and the ‘Procedure for the preparation of Community 
monographs for herbal medicinal products with well-established medicinal use (EMEA/HMPC/182352/2005 
Rev.2) 
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solvent ethanol 45% v/v  1974 
Explanation missing 
D Liquid extract (DER 1:1, extraction solvent ethanol 25% v/v  British Herbal Pharmacopoeia, 
1974 
Explanation missing 
Waiting for Linda earlier editions 
E Dry extract (DER 3.5-4.5:1, extraction solvent ethanol 60% 
v/v) 
Authorised product in Germany, 
on the market at least since 1976 
 
Herbal preparations not considered in the monograph: 
Powdered herbal substance:  
Traditionally suspended in red wine for the treatment of acute unspecific diarrhoea 
(Wichtl 2009). Although the combination with tannins from red wine seems to be 
plausible is this special pharmaceutical form not suitable for THMPs. Weiß (1985) 
proposes a pinch of the powdered herbal substance several times daily. This posology 
seems to be too imprecise. 
Tincture (ratio drug : extraction solvent 1:10), extraction solvent ethanol 70% (v/v) 
This herbal preparation is mentioned only in recent editions of handbooks on 
phytotherapy (e.g., Jänicke et al 2003, Kraft 2000). It seems that the authors refer in the 
proposed posology to the tincture (1:5). 
For the tincture (1:10) mentioned in the market overview of Spain no further information 
on extraction solvent and posology is available. 
 
Combinations of herbal substance(s) and/or herbal preparation(s)8 
Tormentillae rhizoma and it’s preparations are used with many other herbal substances or herbal 
preparations. This monograph refers only to Tormentillae rhizoma. 
 
Vitamin(s)9 
Not applicable 
 
 
Mineral(s)10  
Not applicable 
 
 
 
Information about products on the market in the Member States 
The following information has been provided regarding monographs in national pharmacopoeias or 
products on the market with relevance for this monograph: 
 
CZ:  
Tormentillae radix has been a subject of Czechoslovak/Czech Pharmacopoeia since 1970; 
recommended dosage in the last version of the Czech Pharmacopoeia: single dose for oral use 1.5 
g, daily dose for oral use 4.0 – 6.0 g. 
 
Tormentillae tinctura (ratio drug : extraction solvent 1:5), extraction solvent ethanol 70% (v/v), 
has been a subject of Czechoslovak/Czech Pharmacopoeia since 1970; recommended dosage in 
the last version of the Czech Pharmacopoeia: single dose for local use 0.5 -1.0 g 
                                                           
8  According to the ‘Guideline on the clinical assessment of fixed combinations of herbal substances/herbal 
preparations’ (EMEA/HMPC/166326/2005) 
9  Only applicable to traditional use 
10  
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DK:  
The Danish Food Agency has accepted 200 mg Potentilla erecta, radix in a food supplement. This 
is not an upper limit but a specific assessment in a specific case. 
 
LI: 
The comminuted herbal substance is on the market since more than 30 years. The products are for 
the preparation of infusions for use in the proposed indications. 
 
PL: 
The comminuted herbal substance is on the market since more than 30 years. The products are for 
the preparation of decoctions for use in the proposed indications. 
 
Search and assessment methodology 
• Search terms: Potentilla erecta, Potentilla tormentilla, tormentil, Blutwurz 
• Databases: Pubmed, Medline and Toxnet. 
 
• Libraries: University Vienna, center of pharmacy; Medical University Vienna, central 
library. 
 
Historical data on medicinal use 
 
Information on period of medicinal use in the Community 
The medicinal use of Tormentillae rhizoma can be traced in literature back to the 15th 
century (according to Madaus 1938), it is also mentioned by Lonicerus and Matthiolus in the 
17th century (cited in Benedum et al 2006). 
In fact Tormentillae rhizoma has been in therapeutic use for many decades, a continuous use 
during the last 30 years is documented in the literature. 
Therefore for Tormentillae rhizoma a period of at least 30 years in medicinal use as requested 
by Directive 2004/24 EC for qualification as a traditional herbal medicinal product is easily 
fulfilled. 
 
The type of tradition: European. 
 
Information on traditional/current indications and specified substances/preparations 
 
Tormentillae rhizoma is traditionally used for acute, unspecified diarrhoea, externally for 
haemostasis, mild inflammation of the oral and pharyngeal mucosa, prosthetic pressure 
points, frostbites, burnings, haemorrhoids and poorly healing wounds (Madaus 1983, List & 
Hörhammer 1977, British Herbal Pharmacopoeia 1983, Weiß 1985, Blaschek et al 2008, 
Fintelmann & Weiss 2002, Augustin & Hoch 2004). 
Proposed indications for traditional use: 
Indication 1: 
Traditional herbal medicinal product for short-term use in cases of acute, unspecific 
diarrhoea. 
 
Indication 2: 
Traditional herbal medicinal product for the symptomatic treatment of inflammations in the 
mouth or the throat. 
 
Tormentillae rhizoma is a traditional herbal medicinal product for use in specified indications 
exclusively based upon long-standing use. 
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The high content of tannins makes the medicinal use in the proposed indication plausible. 
 
Specified strength/posology/route of administration/duration of use for relevant preparations and 
indications 
Posology 
Indication 1: Diarrhoea 
 Herbal preparation Posology 
A Comminuted herbal substance. 
for preparation of infusions: 
 
 
 
 
 
 
for preparation of decoctions: 
 
 
 
 
Corresponding 4-6 g herbal substance daily 
(authorised products in Lithuania since more 
than 30 years) 
 
2-4 g thrice daily (British Herbal Pharmacopoeia 
1974) 
 
Corresponding 4-6 g herbal substance daily 
(German Commission E cited in Blumenthal 
1998, Wichtl 2009) 
 
2-3 g in 150 – 200 ml of water: drink 2 x daily 
(authorised products in Poland since more than 
30 years) 
B Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 70% (v/v) 
 
 
30 – 50 drops in water, several times daily 
(Weiß 1985) 
C Tincture: DER 1:5, extraction solvent alcohol 
45% v/v  
2-4 ml thrice daily (British Herbal 
Pharmacopoeia 1974) 
 
D Liquid extract: DER 1:1, extraction solvent 
alcohol 25% v/v  
2-4 ml thrice daily (British Herbal 
Pharmacopoeia 1974) 
 
E Dry extract (DER 3.5-4.5:1, extraction 
solvent ethanol 60% v/v) 
3 times daily 2 capsules, each containing 200 mg 
dry extract 
 
Indication 2: inflammations in the mouth or the throat 
 Herbal preparation Posology 
A Comminuted herbal substance. 
for preparation of infusions  
 
 
 
for preparation of decoctions  
Corresponding 4-6 g herbal substance daily 
(authorised products in Lithuania since more 
than 30 years) 
 
 
2-3 spoons (= 8-12 g) of the rhizome per litre 
water. Rinse the mouth several times daily 
(Fintelmann & Weiss 2002). 
 
Corresponding 4-6 g herbal substance daily 
(German Commission E cited in Blumenthal 
1998, Wichtl 2009) 
 
6 g in 200 ml water: for washing oral cavity 
(authorised products in Poland since more than 
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30 years) 
B Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 70% (v/v) 
 
 
1 teaspoon per glass of water, rinse the mouth 
(Fintelmann & Weiss 2002). 
 
10-20 drops to one glass of water daily 
(Blumenthal et al 1998) 
C Tincture: DER 1 :5, extraction solvent 
alcohol 45% v/v  
no posology available 
D Liquid extract : DER 1 :1, extraction solvent 
alcohol 25% v/v  
no posology available 
E Dry extract (DER 3.5-4.5:1, extraction 
solvent ethanol 60% v/v) 
Not authorised for this indication 
 
Use in children: 
There are no data from clinical trials or observational trials available. Therefore the use 
should be restricted to adults. 
The use of the dry extract was allowed in Germany for adolescents in case of unspecific acute 
diarrhoea. 
 
Duration of use 
Indication 1: 
If the symptoms persist longer than 4 days during the use of the medicinal product, a doctor 
or a qualified health care practitioner should be consulted. 
 
Indication 2: 
If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor 
or a qualified health care practitioner should be consulted. 
 
Method of administration 
Indication 1: 
Oral use 
 
Indication 2: 
Oromucosal use 
 
 
3.1.2. Non-Clinical Data 
 
 
 
Overview of available pharmacological data regarding the herbal substance(s), herbal 
preparation(s) and relevant constituents thereof 
Data obtained with traditional herbal preparations relevant for the proposed indications: 
Antiviral effect: 
 
A decoction (DER 1:10) revealed antiviral activity in a plaque inhibition test against Herpes virus HVP 75 
(type 2) and vaccine virus (May & Willuhn 1978). 
 
Further data: 
Astringent effect: 
 
Tannins as polyphenols exhibit the potential for so called multidentate interactions with other molecules, 
predominately with proteins. The binding on proteins may be irreversible (covalent binding) or reversible 
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(hydrogen bonds). The astringency results from this affinity for proteins. Externally, they waterproof the 
external layers of the skin and mucosas, thus protecting the underlying layers; they also have a 
vasoconstrictor effect on small superficial vessels (Hänsel & Sticher 2007). Thus, the absorption of fluids 
from the intestinal lumen and the influx into this is reduced, the precipitate of the protein-tannin complex 
serves as a protective layer. The absorption of toxins is impeded; the effects of local irritants are reduced 
(Dingermann & Loew 2003). For most of these presumptions no experimental data are available. 
 
Antimicrobial effects: 
 
Tannins exhibit antimicrobial effects independent of their plant source (Hänsel & Sticher 2007). A tannin 
complex isolated from Tormentillae rhizome, which contained tannins, sugar and triterpenes, prevented 
the growth of the following bacteria fully in the following concentrations : 2,5 mg/ml : Pasteurella 
pseudotuberculosis, Shigella boydii, Shigella flexneri, Shigella sonnei; 5mg/ml: Proteus vulgaris, 
Pseudomonas aeruginosa, Staphylococcus aureus; 10mg/ml: Escherichia coli 055B5, E. coli 0111B4, 
streptococcus faecalis (Pourrat et al 1963 cited in Blaschek et al 2008). The mentioned concentrations may 
be reached after consumption of a herbal tea of tormentil. 
 
 
 
Antiinflammatory effect: 
 
Antiinflammatory properties are documented for a wide variety of tannins (Scholz 1994). 
Agrimoniin, a major tannin of tormentil, was identified as a potent direct inhibitor of human neutrophil 
elastase with an IC50 of 0.9 µM (Hrenn et al 2006). 
 
Immunostimulatory effect: 
 
A weak immunostimulating effect was detected with a crude extract prepared with water containing 
acetone. To mice 25 mg crude drug extract per kg bodyweight were applied intraperitoneally. After an 
hour they were given oxazolon to sensitization on the shaved belly. After 7 days oxazolon was applied on 
one ear, which led to an average increase of the ear thick by 24 %. At an increase by 50 %, a substance is 
considered active by the authors. No further details are published regarding the number of mice or 
statistical parameters (Lund & Rimpler 1985). 
 
Drozd & Anuszewska (2005) demonstrated that the combined addition to a culture of decoctions from 
tannin pharmacopoeial raw materials, containing ellagic acid (Cortex Quercus, Folium Uvae ursi and 
Rhizoma Tormentillae, decoction in usual concentration = app. 2 g tormentil per 150 ml water) and the 
antibiotics: cefuroxime, cefoperazone and doxycycline influences the enhancement of survival of mouse 
thymocytes in cultures with supplementation of hydrocortisone. A cytotoxic test was used for the 
evaluation. The presented results confirmed that each of the applied aqueous extracts shows a better 
survival of mouse thymocytes after combined addition of an antibiotic to the culture. The extract from 
Cortex Quercus showed the highest activation when added to the culture with cefuroxime, whereas 
cefoperazone best stimulation demonstrated when combined with the extract from Rhizoma Tormentillae, 
and doxycycline with the extract from Folium Uvae ursi. The authors conclude that the combination of 
antibiotics and tannin raw materials could be advantageous for the immunological system of patients.  
 
Assessor’s comment: the interpretation of the authors seems to be too optimistic. The conclusions made 
are far away from practical consequences. 
 
 
 
Interferon inducing effect: 
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A weak effect was observed in a study on interferon induction. Mice received 100 mg crude drug extract 
per kg bodyweight intraperitoneally. After 17 hours 0,05 ml of a dilution of Vaccinia-virus (IHD strain) 
was applied intravenously. This concentration produced untreated 12 to 25 separate lesions on the tail of 
each animal. Inhibition of these lesions on the eighth day by more than 50 % is interpreted as a possible 
interferon inducing effect. The observed inhibition was approximately 28 %. No further details are 
published regarding the number of mice or statistical parameters (Lund & Rimpler 1985). 
 
Molluscicide effect : 
 
Aqueous and methanol extracts (5 g herbal substance in 100 ml) in concentrations of 400 ppm or 100 ppm 
are still active against the freshwater snail Biomphalaria glabrata, which is the intermediate host of 
schistosomiasis. The molluscicide principle of the drug are the tannins (Schaufelberger & Hostettmann 
1983). 
 
Hypoglycemic effect :  
 
Tormentic acid (isolated from the plant Poterium ancistroides, but also a constituent of tormentil) lowered 
in a concentration of 30 mg/kg BW the fasting plasma glucose level with a corresponding increase in 
circulating insulin levels in rats. It also improved the glucose tolerance test by increasing insulin secretory 
response to glucose. Tormentic acid did not alter the insulin and glucose levels in streptozotocin-induced 
diabetic rats (Ivorra et al 1988). Since no data on the concentration of tormentic acid in tormentil are 
available, the relevance of this publication for the use of tormentil cannot be assessed. 
 
Antioxidant activity: 
Dimers and timers of procyanidins of tormentil displayed the highest anti-radical activity towards 
lipoperoxidation compared to other fractions of a water soluble tormentil extract. The IC50 of a total 
extract was determined with 0.024 mg/ml. Pentamers and hexamers possessed the most marked anti-
elastase properties. The IC50 of a total extract was determined with 0.044 mg/ml. These effects are 
interpreted by the authors as a possible prevention of the aging effects of oxidative membrane impairment. 
No standard antioxidants were included for comparison of the results (Vennat et al 1994, Bos et al 1996). 
 
Chandak et al (2009) investigated pure gallotannin in rats with Streptozotocin (STZ)-induced diabetic 
nephropathy. Poly(ADP-ribose) polymerase (PARP) is known to be activated under conditions of 
oxidative stress and/or radiation exposure. Inhibition of PARP by specific inhibitors is known to prevent 
the development of STZ induced diabetic nephropathy by reduction in oxidative stress induced apoptosis. 
Gallotannin (20 mg/kg/day, i.p.) treatment for 4 weeks led to a significant reduction in the levels of 
plasma creatinine which is a well known marker for diabetic nephropathy. Treatment with gallotannin 
resulted in protection up to a certain level of glomerular damage, suggesting compensatory glomerular 
hypertrophy. As a PARG inhibitor gallotannin treatment also showed protection in PARP cleavage which 
is a hallmark for apoptotic cell death signifying the protective role of gallotannin in cell death signalling. 
 
Tormentil (no details on the herbal preparation and concentration) showed antioxidant activity in a cell-
free oxidant-generating system as well as in sigmoid or rectal mucosal biopsies obtained from patients 
with active ulcerative colitis (Langmead et al 2002). 
 
Effect on histamine release: 
The effects of tannins and related polyphenols on potassium superoxide- and compound 48/80-induced 
histamine release from rat peritoneal mast cells were examined. Pre-treatment with hydrolysable tannins 
(1-100 µM) significantly inhibited potassium superoxide-induced histamine release. For example 
agrimoniin inhibited the potassium superoxide- induced histamine release wirh an IC50 of 0.68 µM, the 
compound 48/80-induced histamine release with an IC50 of 0.49 µM. The inhibitory effect on histamine 
release caused by different stimulants suggested that ellagitannins act as cell membrane stabilizers as well 
as radical scavengers (Kanoh et al 2000). 
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Antitumor effects: 
Agrimoniin (concentration app. 1% in the herbal substance) was identified as a potential antitumor agent 
by Miyamoto et al (1987). Agrimoniin rejected almost completely the growth of ascites type and solid 
type tumours in mice in a dose of 10 mg/kg when applied intraperitoneally. Murayama et al (1992) found 
that agrimoniin induces the interleukin-1 secretion dose-dependently which was interpreted as possible 
mechanism for the antitumor activity.  
 
Miyamoto et al (1988) found that agrimoniin in a dose of 10 mg/kg enhanced in vitro the cytotoxic 
potential of several effector peritoneal exsudate cells with different induction kinetics. The earlier 
response is an enhanced NK cell activity of nonadherent peritoneal exsudate cells, later responses were 
enhanced cytotoxic acitivity of adherent cells and an antibody-dependent macrophage-mediated cytotoxic 
activity. 
 
Assessor’s comment: Considering the low amount of agrimoniin in the herbal substance (about 1%) these 
findings seem to be of minor relevance for the oral and oromucosal use of tormentil. 
 
Overview of available pharmacokinetic data regarding the herbal substance(s), herbal 
preparation(s) and relevant constituents thereof 
 
No specific data are available on Tormentillae rhizoma. 
 
Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) 
and constituents thereof 
Acute Toxicity:  
Dry extract (extraction solvent acetone/water 75:25): in dosages of 300 mg/kg p.o. and 200 mg/kg i.p. no 
signs of toxicity in mice (Lund & Rimpler 1985). 
 
A dry extract prepared by maceration with water was applied to rats and mice by the intragastric route in 
dosages of 2.5 g/kg and 6.8 g/kg respectively. Further, a single dose was applied intraperitoneally in 
dosages of 3.8 g/kg in mice and 14.5 g/kg in rats. No signs of toxicity could be observed, the 
macroscopical and microscopical investigation of the internal organs revealed no pathological changes. 
The tested doses correspond to several hundreds of grams of extract for a person with 75 kg (Shushunov et 
al 2009). 
 
No tests on genotoxicity, carcinogenicity and reproductive toxicity have been performed. 
 
Tannins may have carcinogenic potential; this is for example documented for oak. It is not clear whether 
these findings are relevant for tormentil too.  
 
 
Overall conclusions on non-clinical data 
 
The astringent effect of the tannins makes the use of tormentil plausible in the proposed indications. 
Although the data on toxicology are limited there are no safety concerns for the use as traditional herbal 
medicinal product. 
3.1.3. Clinical Data 
 
Clinical Pharmacology 
 
Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including 
data on relevant constituents 
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There is no data available. 
 
 
Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data 
on relevant constituents 
 
In the study of Huber et al (2007, see II.4.2.1) neither undegraded nor metabolized tannins could be 
detected by LC-MS in 15 patient sera even after application of 3000 mg/d of an ethanolic dry extract. 
No data are available regarding further constituents of tormentil. 
Clinical Efficacy  
Dose response studies 
In an open-label study Huber et al (2007) investigated the safety, pharmacology and clinical effects of 
different doses of a commercial ethanolic dry extract (tannin content 15-22%, no further data available). 
15 patients with active ulcerous colitis finished the study. During treatment with Tormentil extracts, the 
CAI (Colitis activity index) was reduced from a mean of 8.3 to 3.9 when participants took 2400 mg/d, 
which was statistically significant. In addition, stool frequency, bloody stool and C-reactive protein 
decreased. Although the posology was very high the reported adverse effects were mild (heartburn, 
stomach discomfort, nausea).  
 
Clinical studies (case studies and clinical trials) 
There is no data available. 
 
Clinical studies in special populations (e.g. elderly and children) 
 
40 children in the age from 3 months to 7 years suffering from a rotavirus diarrhoea were included in a 
clinical trial by Subbotina et al (2003). The children in the active group received 3 drops tormentil extract 
per year of life three times daily until discontinuation of the diarrhoea or at maximum for 5 days. The 
study medication was a tincture (1:10, extraction solvent ethanol 40%). The placebo was an alcohol 
extract of Indian teas which were identical in appearance and taste with tormentil tincture. 
The duration of the diarrhoea was in the treatment group 3 days, in the placebo group 5 days. 
No side effects were reported. 
 
Assessor’s comment:  
The data support the traditional use of tormentil for the treatment of diarrhoea. 
 
Overall conclusions on clinical pharmacology and efficacy 
The published clinical trials give only preliminary data. They support the traditional use of tormentil. 
However, the level of evidence does not support well-established use. 
 
3.1.4. Clinical Safety/Pharmacovigilance 
 
Overview of toxicological/safety data from clinical trials in humans 
 
There is no data available. 
 
Patient exposure 
 
None reported. 
Adverse events and serious adverse events and deaths 
 
The only source of documented adverse effects is the study by Huber et al (2007). All side effects were 
mild, although 62 % experienced mild gastrointestinal symptoms. One of the 15 patients developed 
worsening of colitis and was hospitalized. 
 21 
 
 
Laboratory findings 
 
There is no specific data available. 
 
Safety in special populations and situations 
There is no specific data available. 
 
Overall conclusions on clinical safety 
The medicinal use of Tormentillae rhizoma can be regarded as safe. 
 
3.1.5. Overall Conclusions 
Risk – benefit assessment: 
Since no specific risks are known regarding the oral and oromucosal use of herbal 
preparations of tormentil, there are no limitations from the herbal preparation when used in 
adults.  
Persistent diarrhoea may cause dehydration and loss of electrolytes. Rehydration and 
substitution of electrolytes are the primary therapeutic goals. Acute, unspecific diarrhoeas are 
in most cases self-limiting diseases, a supportive treatment with astringents like tormentil 
may help to reduce the duration and the severity of the complaints. However, if the symptoms 
persist for more than 2 days the diarrhoea should be treated and monitored by a doctor. 
Only limited data are available regarding the use of tormentil in children and adolescents in 
the case of diarrhoea. Astringents like purified tannins are recommended in standard 
literature for children because of their safety compared to therapeutic alternatives (Mutschler 
et al 2008). However, acute diarrhoea may be life-threatening especially for young children 
when not properly treated. Therefore the use of tormentil in the case of diarrhoea in children 
is not suitable for a traditional herbal medicinal product. 
The use as a gargle in the case of inflammations in the mouth does not show any limitations. 
However, there are no data regarding a posology in children and adolescents available. 
Therefore the use should be limited to adults. 
No data are available on the safe use during pregnancy and lactation. Therefore the use of 
tormentil is not recommended during pregnancy and lactation. 
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COMMUNITY HERBAL MONOGRAPH ON POTENTILLA ERECTA (L.) RAEUSCH, 
RHIZOMA 
 
NAME OF THE MEDICINAL PRODUCT 
 
To be specified for the individual finished product. 
 
 
QUALITATIVE AND QUANTITATIVE COMPOSITION1213 
 
Well-established use  
 
With regard to the marketing authorisation 
application of Article 10(a) of Directive 
2001/83/EC as amended 
 
 
Traditional use  
 
With regard to the registration application of 
Article 16d(1) of Directive 2001/83/EC as 
amended 
 
Potentilla erecta (L.) Raeusch., rhizoma 
(tormentil) 
 
Herbal substance 
not applicable 
 
Herbal preparations 
A) Comminuted herbal substance  
B) Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 70% (v/v) 14 
C) Tincture (ratio drug : extraction solvent 1:5), 
extraction solvent ethanol 45% v/v 
D) Liquid extract (DER 1:1, extraction solvent 
ethanol 25% v/v) 
E) Dry extract (DER 3.5-4.51, extraction solvent 
ethanol 60% v/v) 
 
 
PHARMACEUTICAL FORM 
 
Well-established use 
 
 
 
 
Traditional use 
Comminuted herbal substance as herbal tea for 
oral use. 
Comminuted herbal substance for infusion or 
decoction preparation for oromucosal use. 
Herbal preparations B, C, D and E in liquid 
dosage forms for oral use. 
Herbal preparation B in liquid dosage forms for 
oromucosal use. 
The pharmaceutical form should be described by 
the European Pharmacopoeia full standard term. 
                                                           
12 The material complies with the Eur. Ph. monograph (ref.: 01/2008: 1478). 
13 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant 
herbal quality guidance. 
14 The tincture complies with the Eur. Ph. monograph (ref.: 01/2008: 1895). 
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CLINICAL PARTICULARS  
 
Therapeutic indications 
 
Well-established use 
 
 
Traditional use 
Indication 1: 
Traditional herbal medicinal product for 
symptomatic treatment of mild diarrhoea. 
 
Indication 2: 
Traditional herbal medicinal product for the 
symptomatic treatment of minor inflammations of 
the oral mucosa. 
 
The product is a traditional herbal medicinal 
product for use in specified indications 
exclusively based upon long-standing use.  
 
Posology and method of administration 
 
Well-established use 
 
 
Traditional use 
 
Posology 
Indication 1 (oral use): 
Adults, elderly: 
A) Comminuted herbal substance: 
As infusion: single dose 1.4-4 g, several times 
daily up to a maximum daily dose of 12 g 
comminuted herbal substance. 
As decoction: single dose 1.4-3 g, several times 
daily up to a maximum daily dose of 6 g 
comminuted herbal substance. 
 
B) Single dose: 1-2 ml in water; 3 times daily. 
 
C) Single dose 2-4 ml, 3 times daily. 
 
D) Single dose 2-4 ml, 3 times daily. 
 
E) Single dose 400 mg, 3 times daily. 
 
The use in children and adolescents under 18 
years of age is not recommended (see section 4.4 
‘Special warnings and precautions for use’). 
 
 
Indication 2 (oromucosal use): 
Adults, elderly: 
A) Comminuted herbal substance: 
As infusion: 1.3 – 2 g per 100 ml of water. 
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As decoction: 0.8 – 3 g per 100 ml of water. 
 
Rinse the mouth several times daily. 
 
B) Single dose: 1-5 ml per 150 ml of water. 
 
Rinse the mouth several times daily. 
 
 
The use in children and adolescents under 18 
years of age is not recommended (see section 4.4 
‘Special warnings and precautions for use’). 
 
 
Duration of use 
Indication 1: 
If the symptoms persist longer than 3 days during 
the use of the medicinal product, a doctor or a 
qualified health care practitioner should be 
consulted. 
 
Indication 2: 
If the symptoms persist longer than 1 week during 
the use of the medicinal product, a doctor or a 
qualified health care practitioner should be 
consulted. 
 
 
Method of administration 
Indication 1: 
Oral use. 
 
Indication 2: 
Oromucosal use. 
 
 
Contraindications 
 
 Traditional use 
Hypersensitivity to the active substance 
 
 
Special warnings and precautions for use 
 
Well-established use 
 
 
Traditional use 
Indication 1: 
If recurrent diarrhoea or bloody stools occur a 
doctor or a qualified health care practitioner 
should be consulted. 
 
Indications 1 and 2: 
The use in children and adolescents under 18 
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years of age has not been established due to lack 
of adequate data. 
 
If the symptoms worsen during the use of the 
medicinal product, a doctor or a qualified health 
care practitioner should be consulted. 
 
For tinctures containing ethanol, the appropriate 
labelling for ethanol, taken from the ‘Guideline 
on excipients in the label and package leaflet of 
medicinal products for human use’, must be 
included. 
 
Interactions with other medicinal products and other forms of interaction 
 
Well-established use 
 
Traditional use 
 
Indication 1: 
Internal absorption of concomitantly administered 
medicine may be delayed. For this reason the 
product should be taken 1 hour or more before or 
after intake of other medicinal products. 
 
Indication 2: 
None reported. 
 
 
Pregnancy and lactation 
 
 Traditional use 
Safety during pregnancy and lactation has not 
been established. 
In the absence of sufficient data, the use during 
pregnancy and lactation is not recommended. 
 
 
 
Effects on ability to drive and use machines 
 
Well-established use 
 
Traditional use 
 
No studies on the effect on the ability to drive and 
use machines have been performed. 
 
 
Undesirable effects 
 
Well-established use 
 
 
Traditional use 
Indication 1: 
Mild stomach complains with the symptoms 
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nausea and vomiting may occur in sensitive 
patients. The frequency is not known. 
 
If other adverse reactions not mentioned above 
occur, a doctor or a qualified health care 
practitioner should be consulted. 
 
Indication 2: 
None known. 
 
If adverse reactions occur, a doctor or a qualified 
health care practitioner should be consulted. 
 
Overdose 
 
Well-established use 
 
 
Traditional use 
 
No case of overdose has been reported. 
 
 
PHARMACOLOGICAL PROPERTIES 
 
Pharmacodynamic properties 
 
Well-established use 
 
 
Traditional use 
 
Not required as per Article 16c(1)(a)(iii) of 
Directive 2001/83/EC as amended. 
 
Pharmacokinetic properties 
 
Well-established use 
 
 
Traditional use 
 
Not required as per Article 16c(1)(a)(iii) of 
Directive 2001/83/EC as amended. 
 
 
 
Preclinical safety data 
 
Well-established use 
 
 
Traditional use 
 
Not required as per Article 16c(1)(a)(iii) of 
Directive 2001/83/EC as amended, unless 
necessary for the safe use of the product. 
 
Adequate tests on reproductive toxicity, 
genotoxicity and carcinogenicity have not been 
performed. 
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PHARMACEUTICAL PARTICULARS 
Well-established use 
 
 
Traditional use 
 
 
 
DATE OF COMPILATION/LAST REVISION 
 
13.01.2010 
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3.2. SYZYGIUM AROMATICUM (L.) MERRILL. ET L.M. PERRY, FLOS, SYZYGIUM AROMATICUM 
(L.) MERRILL. ET L.M. PERRY, AETHEROLEUM 
 
 
 
COMMITTEE ON HERBAL MEDICINAL PRODUCTS 
(HMPC) 
 
 
 
 
ASSESSMENT REPORT ON 
SYZYGIUM AROMATICUM (L.) MERRILL. ET L.M. PERRY, FLOS, 
SYZYGIUM AROMATICUM AETHEROLEUM15  
 
 
 
                                                           
15 Botanical name of the plant according to the binomial system (genus, species, variety and author), [comma] the 
plant part in Latin. 
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REGULATORY STATUS OVERVIEW16 
MA: Marketing Authorisation  
TRAD: Traditional Use Registration  
Other TRAD: Other national Traditional systems of registration  
Other: If known, it should be specified or otherwise add ’Not Known’ 
Member State Regulatory Status Comments17 
Austria  MA  TRAD  Other TRAD  Other Specify:  Combinations only 
Belgium  MA  TRAD  Other TRAD  Other Specify:  Food supplements 
Bulgaria  MA  TRAD  Other TRAD  Other Specify:  no response 
Cyprus  MA  TRAD  Other TRAD  Other Specify:  no response 
Czech Republic  MA  TRAD  Other TRAD  Other Specify:  no response 
Denmark  MA  TRAD  Other TRAD  Other Specify:  no response 
Estonia   MA  TRAD  Other TRAD  Other Specify:  no response 
Finland  MA  TRAD  Other TRAD  Other Specify:  no response 
France  MA  TRAD  Other TRAD  Other Specify:  no response 
Germany  MA  TRAD  Other TRAD  Other Specify:  no response 
Greece  MA  TRAD  Other TRAD  Other Specify:  no response 
Hungary  MA  TRAD  Other TRAD  Other Specify:  Combinations only 
Iceland  MA  TRAD  Other TRAD  Other Specify:  no response 
Ireland  MA  TRAD  Other TRAD  Other Specify:  no response 
Italy  MA  TRAD  Other TRAD  Other Specify:  no response 
Latvia  MA  TRAD  Other TRAD  Other Specify:  Food supplements 
Liechtenstein  MA  TRAD  Other TRAD  Other Specify:  no response 
Lithuania  MA  TRAD  Other TRAD  Other Specify:  no response 
Luxemburg  MA  TRAD  Other TRAD  Other Specify:  no response 
Malta  MA  TRAD  Other TRAD  Other Specify:  no response 
The Netherlands  MA  TRAD  Other TRAD  Other Specify:  no response 
Norway  MA  TRAD  Other TRAD  Other Specify:  no response 
Poland  MA  TRAD  Other TRAD  Other Specify:  no response 
Portugal  MA  TRAD  Other TRAD  Other Specify:  no response 
Romania  MA  TRAD  Other TRAD  Other Specify:  no response 
Slovak Republic  MA  TRAD  Other TRAD  Other Specify:  Combinations only 
Slovenia  MA  TRAD  Other TRAD  Other Specify:  no response 
Spain  MA  TRAD  Other TRAD  Other Specify:  No product 
Sweden  MA  TRAD  Other TRAD  Other Specify:  no response 
United Kingdom  MA  TRAD  Other TRAD  Other Specify:   
                                                           
16 This regulatory overview is not legally binding and does not necessarily reflect the legal status of the products in 
the MSs concerned. 
17 Not mandatory field 
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ASSESSMENT REPORT  
 
BASED ON ARTICLE 16D(1), ARTICLE 16F AND ARTICLE 16H OF DIRECTIVE 2001/83/EC 
AS AMENDED 
(TRADITIONAL USE> 
 
 
Herbal substance(s) (binomial scientific name of 
the plant, including plant part) 
Syzygium aromaticum, flos,  
Szygium aromaticum, aetheroleum 
Herbal preparation(s)  
Pharmaceutical forms18  
Rapporteur19 Austria 
Assessor(s)20 Reinhard Länger, Birgit Hochenegg 
 
3.2.1. Introduction 
Description of the herbal substance(s), herbal preparation(s) or combinations thereof 
Herbal substance(s) 21: 
According to the European Pharmacopoeia Caryophylli flos consists of the dried flower buds of Syzygium 
aromaticum (L.) Merrill. et L.M. Perry which were dried until they become reddish brown. They contain 
not less than 150 ml/kg essential oil. 
Caryophylli floris aetheroleum is according to the European Pharmacopoeia obtained by steam distillation 
from the dried flower buds of Syzygium aromaticum (L.) Merrill et L.M. Perry.  
 
Constituents (according to Blaschek et al 2008): 
 
Essential oil: 15 – 17 %, other sources 16 – 21 %, three main components: eugenol (70 – 90 %), eugenyl 
acetate (- 17 %), caryophyllene (5 – 12 %), main β-caryophyllene, account for 99% of the oil. 
 
Monoterpenes: eugenol (C10H12O2,Mr164,2) is the chief constituent of caryophylli floris aetheroleum, 
making up 60 – 95%, moreover it contains 2 – 15% eugenyl acetate (C12H14O3,Mr206,2), chavicol, (Z)- 
und (E)-isoeugenol,  benzylacetate, α- und β-pinen, limonene 
 
Sesquiterpenes: 5 to 10% β-caryophyllene and the accompanying substances α-ylangene, γ- und α-
caryophyllene (= humulene), caryophyllene epoxid, caryophyllenoxide, caryophylla-3(12),7(13)-dien-6 α-
ol und caryophylla-3(12),6-dien-4-ol [39] sowie 4,4-dimethyltricyclo[6.3.2.02.5]trideca-8-en-1-ol, 
caryophylla-4(12),8(13)-dien-5β-ol, caryophylla-3,8(13)-dien-5 α-ol und caryophylla-3,8(13)-dien-5β-ol, 
α-copaen, α-cubeben, farnesol 
 
Aldehyde: benzaldehyde, m-methoxybenzaldehyde 
 
Alcohols: benzyl alcohol 
 
Ketone: the flavorings heptan-2-one (= methyl-n-amylketone) und octan-2-one (= methylheptylketone) 
 
Hydrocarbons: naphthalene 
                                                           
18 Pharmaceutical form only according to EDQM standard term 
19 Name of HMPC/MLWP member (not Member State) 
20 To be deleted at publication stage, unless Rapporteur requests to keep the name(s) 
6 According to the ‘Procedure for the preparation of Community monographs for traditional herbal medicinal 
products’ (EMEA/HMPC/182320/2005 Rev.2) and the ‘Procedure for the preparation of Community 
monographs for herbal medicinal products with well-established medicinal use (EMEA/HMPC/182352/2005 
Rev.2) 
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Acetophenonderivate:   2,6-dihydroxy-4-methoxyacetophenone, methylxanthoxylin 
 
Flavone: quercetin, kaempferol, kaempferid, rhamnetin, kaempferol-3-O-β-D-glucoside, 
quercetin-3- O-β-D-glucoside, quercetin-3-O-β-D-galactoside, quercetin-3,4′-O-β-D-diglucoside 
 
Tannins: ellagitannins, including eugeniin 
 
Penol acids: gallic- and ellagic acid, 3- und 4-caffeoyl-, 3-p-cumaroyl- and 3-feruloylchina acid, 
ferulic, p-hydroxybenzoic, coffee, salicylic, syringa, vanillic, gentisic, protocatechuic and  p-coumaric 
acid 
 
Triterpene: oleanolic acid, crataegolic acid 
 
Phytosterols: β-sitosterol, stigmasterol, campesterol 
 
Sugars: glucose, xylose, arabinose  
 
 
Herbal preparation(s): 
No references could be found on the medicinal use of Caryophylli flos in authorised or registered 
products. 
 
Herbal preparations: Caryophylli aetheroleum 
The essential oil is traditionally used since decades for the temporary relief of toothache and as 
mouthwash for disinfection of the oral cavity (e.g. Frerichs et al 1938). The essential oil is the only active 
substance of several authorised medicinal products in UK. Although none of these products fulfils the 
criterion of 30 years of medicinal use (authorisation dates back to 1988), the evidence on traditional 
medicinal use is given by a large number of publications providing consistent information. 
 
Combinations of herbal substance(s) and/or herbal preparation(s)22 
The use of Caryophylli flos, Caryophylli foris aetheroleum and it’s preparations is not described with 
other herbal substances or herbal preparations. This monograph refers only to Caryophylli flos, 
Caryophylli foris aetheroleum. 
 
 
Vitamin(s)23 
Not applicable. 
 
 
Mineral(s)10  
Not applicable. 
 
 
Information about products on the market in the Member States 
 
Austria: only combination products 
 
Belgium: food supplements and combination products 
                                                           
22  According to the ‘Guideline on the clinical assessment of fixed combinations of herbal substances/herbal 
preparations’ (EMEA/HMPC/166326/2005) 
23  Only applicable to traditional use 
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Lativia: food supplements and combination products 
 
Slovak Republic: only combination products 
 
Spain: No product 
 
United Kingdom: Several products containg Caryophylli aetheroleum are authorised.  
 
Search and assessment methodology 
Search terms: Syzygium aromaticum, Gewürznelke, Caryophylli flos, eugenol 
Databases: Pubmed, Medline and Toxnet. 
Libraries: University Vienna, center of pharmacy; Medical University Vienna, central library. 
 
3.2.2. Historical data on medicinal use 
 
Information on period of medicinal use in the Community 
The medicinal use of Caryophylli flos can be traced in literature back to the 13th century (cited in 
Benedum et al 2006), it is also mentioned by Matthiolus and Lonicerus in the 17th century (cited in 
Benedum et al 2006). 
In fact Caryophylli flos has been in therapeutic use for many decades. 
Therefore for Caryophylli flos a period of at least 30 years in medicinal use as requested by Directive 
2004/24 EC for qualification as a traditional herbal medicinal product is easily fulfilled. 
The medicinal use of Caryophylli floris aetheroleum can be traced in literature back to the 15th century 
(according to Gildemeister & Hoffmann 1899), it is also mentioned by Schröder and Vietz in the 17th 
and18th century (cited in Benedum et al 2006). 
In fact Caryophylli floris aetheroleum has been in therapeutic use for many decades. 
Therefore for Caryophylli floris aetheroleum a period of at least 30 years in medicinal use as requested by 
Directive 2004/24 EC for qualification as a traditional herbal medicinal product is easily fulfilled. 
 
Documented use in authorised/registered herbal medicinal products with clove essential oil as the only 
active ingredient: 
UK: since 1988 
 
The type of tradition: European. 
Information on traditional/current indications and specified substances/preparations 
Caryophylli flos is traditionally used as spice, for example for gingerbread flavouring. Many spice blends, 
including curry contain powdered cloves; most bitter liqueurs contain clove macerates (Blaschek et al 
2008). 
The Commission E monographs indicate the use of cloves in inflammatory changes of the oral and 
pharyngeal mucosa and in dentistry, for topical anaesthesia (Blumenthal et al 1998). Clove has been 
traditionally used in dyspeptic complaints, flatulence and diarrhoea as a decoction. With foul-smelling 
breath chew a clove over time (Blaschek et al 2008). 
 
Caryophylli flos is a traditional herbal medicinal product for use in specified indications exclusively based 
upon long-standing use. 
Caryophylli floris aetheroleum is traditionally used for external or local applications for the treatment of 
toothache, and minor infections of the mouth and skin, dressing of minor wounds, sore throats and coughs 
associated with the common cold, Caryophylli floris aetheroleum or eugenol alone mixed with filling 
material (zinc oxide) as temporary filling, myalgia, rheumatic complaints, insect bites, flatulent colic, 
nausea (Blaschek et al 2008, WHO Monographs 2002, Koch 1953, Dingermann et al 2004, Barnes et al 
2002, Frerichs et al 1938).  
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Use as a repellent: Especially suitable for the prevention of mosquito bites.  
Cosmetics: Clove oil is used for perfuming of soaps, toothpastes and oral hygiene.  
Household / spices: To flavour alcoholic beverages (type bitters and vermouth), confectionery, bakery 
products and sauces (Blaschek et al 2008). 
 
Indications of authorised/registered herbal medicinal products: 
UK: For the temporary relief of toothache due to a dental cavity 
 
Proposed indication: For the temporary relief of toothache due to a dental cavity and for the treatment of 
minor inflammations of the symptomatic treatment of minor inflammations in the mouth or the throat. 
Caryophylli floris aetheroleum is a traditional herbal medicinal product for use in specified indications 
exclusively based upon long-standing use. 
The high content of eugenol makes the medicinal use in the proposed indication plausible. 
 
Specified strength/posology/route of administration/duration of use for relevant preparations and 
indications 
Posology 
The herbal substance is not used in defined products; no medicinal product can be traced during the last 
decades. The essential oil is contained in mouth washes; according to the German Commission E herbal 
medicinal products should contain the essential oil in a strength of 1-5% (Blumenthal et al 1998). 
For the use in children between 1 and 4 years of age a strength of 1 – 2%, for children older than 4 years 
and adolescents a strength of 1 – 5% are suggested (Dorsch et al 2002). 
Duration of use 
Not applicable. 
Method of administration 
The oromucosal and oral administration are the only ways of administration (Blaschek et al 2008). 
 
3.2.3. Non-Clinical Data 
 
Overview of available pharmacological data regarding the herbal substance(s), herbal 
preparation(s) and relevant constituents thereof 
 
Effects of Caryophylli flos: antiseptic, antibacterial, antifungal, antiviral, local anaesthetic and 
spasmolytic effects are attributed to the drug. This information is only partially covered by experimental 
work (Blaschek et al 2008). 
 
Antimicrobial effects: The additive of 1 g clove powder to 9 ml culture medium inhibited the growth of 
Aspergillus flavus, A. ocharceus and A. versicolor totally (Hitokoto et al 1980). 
 
A MeOH extract from the dried buds of S. aromaticum L. (clove) demonstrated preferential antimicrobial 
activity against the periodontal pathogens Prevotella intermedia and Porphyromonas gingivalis with MICs 
of 156 and 625 µg/ml (Cai &Wu 1996). 
 
Synergism between 13 antimicrobial drugs and 8 plant extracts against Staphylococcus aureus strains. S. 
aromatium L. showed the highest activity. The MIC 90% range was 0,36 mg/ml for clove. Clove extract 
presented synergism with 11 of 13 drugs so the synergistic capacity was promising (Betoni et al 2006). 
 
Antiviral effect: An aqueous extract of clove combined with acyclovir showed a stronger anti-HSV-1 
activity as treatment with acyclovir alone. No signs of toxicity of the herbal preparation were observed 
after administration of 250 mg/kg BW for 7 days (Kurokawa et al 1995). 
 
Anticarcinogenic effects: DMBA-croton oil treated mice had a visible rough granular surface on the 
shaved skin with varying degrees of erythema and sometimes with white plaque like lesion. Treatment 
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with aqueous infusion of clove delayed the onset of papillomas in treated groups. Treatment was most 
effective in the group which receive the clove infusion orally. At the dose of 100 µl the onset of papilloma 
was delayed by two weeks. 200 µl clove infusion also delayed onset of papilloma but not to the extent 
seen with 100 µl. 50 µl of clove infusion were not effective (Banerjee & Das 2005).  
The effect of clove aqueous infusion was very pronounced (p < 0,01) on the incidence of carcinoma in situ 
(CIS). The infusion was administered at a dose of 100 µl/mouse/day. While 70% of Benzopyrene-exposed 
animals (Newborn Strain A mice) had CIS, after treatment with clove infusion only 10% animals showed 
CIS indicating 85,71% inhibition after such treatment. Incidence of hyperplasia and dysplasia evident in 
the carcinogen control group, were effectively reduced after treatment with clove infusion. Significant 
reduction in the number of proliferating cells and an increased number of apoptotic cells was also noted in 
these Benzopyrene-induced lung lesions following clove treatment (Banjeree et al 2006). 
 
Assessor’s comment: These observations support the idea that spices possess anticarcinogenic properties 
and may contribute to maintain health. 
 
Molluscicidal effect: The snail Lymnaea acuminata is the intermediate host for Fasciola-species causing 
fascioliasis in northern India. The toxicity of flower-bud powder of Syzygium aromaticum L. and its 
organic solvent extracted fractions against the snail Lymnaea acuminata were time and concentration 
dependent. The LC50 of flower-bud powder of Syzygium aromaticum L. at 24 h was172,75 mg/l and at 
96 h 51,98 mg/l, respectively. Ethanol extract was more toxic than other organic extracts. The 24 h LC50 
of ethanol extract of S. aromaticum flower-bud powder against L. acuminata was 83,53 mg/l. The 24 h 
LC50 of the column purified fractions of S. aromaticum flower-bud powder was 20,73 mg/l; 96 h LC50 
7,87 mg/l. 24 h LC50 of eugenol was 11.03 mg/l (Kumar & Singh 2006). 
 
Assessor’s comment: These results clearly indicate that flower-bud powder of Syzygium aromaticum L. 
could be an important source of molluscicides. 
 
Sexual behaviour:  
The effects of an ethanolic extract of clove (DER app. 10:1, ethanol 50%) were evaluated and compared 
with the standard drug Sildenafil citrate. The extract was administered orally to adult male Swiss mice at a 
dosage of 500mg/kg. Clove ethanolic extract and the standard drug Sildenafil displayed excessive 
mounting behaviour 1 hour after treatment as well as 3 hours after treatment (Tajuddin et al 2003). 
The extract increased the mounting frequency, intromission frequency, ejaculatory latency in first series 
and decreased the mounting latency, intromission latency in a significant manner. At doses of 100 mg/kg 
no significant change of the mounting frequency was observed. No signs of toxicity were observed 
(Tajuddin et al 2004). 
 
 
Other effects: Male, 7 to 8 weeks old swiss-albino mice were given over 10, 20 or 30 days feed with 0,5%, 
1% and 2% (m/m) clove powder. The content of acid-soluble, free SH-groups in the liverhomogenate 
increased significantly dose- and time-dependent compared to untreated controls. After 30 days 27, 79 or 
30.01 or 33,10 µmol/g tissue (control 19,89 µg/g; p < 0,005) were found. The formation of 
malondiealdehyde was reduced after γ –irradiaton: 30 days, 1,90 (p <0,01), 1,01 or 0,89 (p < 0,0005) 
nmol/mg protein; control 2,29 nmol/mg protein. The Glutathion-S-Transferase activity and the 
cytochrome- b5-content was in all groups (with the exception 0, 5%, 10 days) increased significantly 
compared with controls (p <0,0005 to p < 0,01). The cytochrom-P450-content fell significantly in all dose 
groups after 30 days. The activity of arylhydrocarbonhydroxylase was unaffected. A possible protective 
effect of the herbal substance against chemical pollutants is discussed (Kumari 1991). 
 
A methanol extract from cloves induced the differentiation of M1-cells (myelotic leukaemia of mouse) in 
macrophage in vitro. The fractionation of the extract yielded oleanolic acid and crategolic acid as active 
ingredients, which induce in a concentration of 5 × 10–5 or 2 × 10–5 M a differentiation. Oleanolic acid 
resulted in a concentration of 5 ×10–6 M also in a differentiation of HL-60 cells (promyelotic human 
leukaemia) while the effect of crategolic acid was overlaid by cytotoxic effects. The authors investigated 
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by means of derivates structure-activity-relationships. There is a lack on further pharmacological 
information (Umehara et al 1992)  
 
Clove infusion reduced the COX-2 level on the 17th and 26th weeks but not on the 8th week (Banjeree et 
al 2006). 
Anti-Hepatitis C Virus Protease-activity was caused by Syzygium aromaticum.  The methanol extract 
exhibited significant inhibitory activity (≥ 90% inhibition). The IC50 was 33, 0 µg/ml (Hussein et al 
2000). 
 
The toxic effect of cloves on Culex pipiens larvae, the common European mosquito, was investigated by 
El Hag et al (1999). The LC50 for the methanol extract was 824, 7 ppm (assay time: 6 days) and the LC50 
for the ethanol extract was 921,3 ppm (assay time: 6 days). The highest mortality (70%) was obtained in 
the 1000ppm concentration after 10 days. 
Antithrombotic effects: Two different polysaccharides with rhamnogalacturan backbone and arabinan side 
chain were isolated which exhibit antithrombotic activity. After intravenous application of the low 
molecular weight polysaccharide (MW 34.000) in doses up to 1000 mg/kg BW in mice no signs of acute 
toxicity were observed, while the high molecular weight polysaccharide (MW 103.000) exhibited 
approximately half the toxicity of heparin (LD50 322 mg/kg) (Lee et al 2001). 
 
Antiallergic effects: Kim et al (1998) investigated the effect of a hot water extract (DER app. 14:1) of 
clove on the immediate hypersensitivity in rats. The extract inhibited the compound 48/80-induced 
systemic anaphylaxis in rats with an IC50 of 31.25 mg/kg when administered intraperitoneally. The 
extract also inhibited the local immunoglobulin E-mediated passive cutaneous anaphylactic reaction (IC50 
= 17.78mg/kg, i. v., IC50 = 19.81 mg/kg, p. o.). The extract also inhibited dose-dependently the induced 
histamine release from rat peritoneal mast cells. 
 
Effect on NO-formation: A decoction (0.1%) 0f cove reduced NO levels by 57.2%, in comparison with the 
control value at a concentration of 250 µg/ml. The scavenging effects were concentration-dependent 
(Yokozawa et al 2000). 
 
Antioxidative effects: A decoction (10%) of clove exhibited antioxidative effects on the lipid peroxidaton 
and protein oxidative modification of mice brain homogenate produced by copper in vitro (Toda 2001, 
Toda 2003). 
  
Effects of Caryophylli floris aetheroleum:  
Due to a high content of eugenol in Caryophylli floris aetheroleum, the effects of eugenol are claimed for 
the essential oil as such.  
Eugenol acts spasmolytic, choleretic, local anaesthetic and it inhibits the motility, as well as a spasmolytic 
and local anaesthetic effect of eugenyl acetate (Gracza 1980 cited in Blaschek et al 2008). 
 
Analgesic effects: Patch-clamp experiments showed that eugenol reversibly activates calcium ion channels 
and chloride ion channels in dorsal root ganglion cells from rats. Eugenol concentrations used were from 
0,125 to 1 mmol/l. These effects may be the responsible for the analgesic activity (Gruenwald et al 2004). 
Caryophyllene oxide and eugenol as Ca++-channel-blockers (Sensch et al 1993 cited in Blaschek et al 
2008).  
 
Natrium and Calcium channels act as molecular targets for eugenol for its analgesic effect. Eugenol 
inhibits ATP-induced P2X currents in trigeminal ganglion neurons, which contributes to the analgesic 
effect (Li et al 2008).  
Intrathecal treatment of mice with eugenol (12.5 to 50 µg) for 24 hours dose-dependently inhibited the 
formalin-induced nociceptive response. Capsazepine shifted the dose-response curves in parallel to the 
right. Eugenol may exert its antinociceptive effect via the capsaicin receptor located on sensory terminals 
in the spinal cord. These results are novel findings indicating that eugenol act as capsaicin-like substance 
(Ohkubo & Shibata1997).  
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Antiinflammatory effects: Eugenol inhibited the NO production in a dose-dependent manner in the 
RAW264,7 cells treated with 1 µg/ml Lipopolysaccharid for 24 h. Isoeugenol was more effective. LPS-
dependent expression of COX-2 was also inhibited by isoeugenol and less effectively by eugenol (Li et al 
2006).  
 
Anticarcinogenic effects: The sesquiterpenes ß-caryophyllene, ß-caryophyllene oxide, alpha-humulene, 
alpha-humulene epoxide and eugenol induced the detoxifying enzyme glutathione S-transferase in the 
mouse liver and intestine. These compounds show promise as potential anticarcinogenic agents. Mice got 
20 mg of isolated sesquiterpenes once every 2 days (Zheng et al 1992). 
Eugenol showed chemo preventive effects. Eugenol, but not its isomer isoeugenol was found to be a 
potent inhibitor of melanoma cell proliferation. It inhibits the growth of melanoma cells in culture (50% 
inhibition by 0.5 µM). Eugenol causes significant tumour growth delay, decrease of tumour size and 
prevents tumour metastasis in mice (125 mg/kg) (Ghosh et al 2005).  
 
Antimicrobial effects: The majority of publications on pharmacological effects of clove or clove essential 
oil deal with the antimicrobial effects. Only some selected references are cited below. 
0, 4% clove oil in 63% sugar syrup inactivated after 2 – 7 min Candida albicans, Clostridium perfringens, 
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa und Staphylococcus aureus. The effect 
was not affected by addition of serum. Added sugar is not needed for an effect; however, it stabilizes the 
dispersion of the essential oil (Briozzo et al 1989). 
 
The effect of 0 – 300 ppm clove oil on the growth and synthesis of aflatoxins from Aspergillus parasiticus 
was studied in submerged culture. 0 – 250 ppm made a slower growth, but had no influence on the 
mycelweight after 21 days. 300 ppm completely inhibited the growth. The aflatoxinproduction was dose-
dependent delayed. With 250 ppm the maximum aflatoxinproduction of the control was not achieved even 
after 3 weeks (Bullerman et al 1977). 
 
In an investigation of various aromatic waters, clove oil – water had no sustainable growth-inhibiting 
effect in load with pseudomonas. Clove oil exhibited in the serial dilution test and agar diffusion test only 
a weak antimicrobial effect. The MHC in the serial dilution test was in the case of Bacillus subtilis, 
Escherichia coli and Pseudomonas aeruginosa for each 1:20, for Mycobacterium phlei 1:640 and for 
Staphylococcus aureus 1:160 or 1:320. The minimal fungicidal dilution was 1:320 in case of Aspergillus 
niger, for Penicillium chrysogenum 1:40 and for Mucor, Rhizopus and Candida albicans for each 1:20. 
The results in agar diffusion test differ in part from that in the serial dilution test (Yousef & Tawil 1980). 
 
Ali et al (2005) found that eugenol inhibits the growth of 30 Helicobacter pylori strains tested, at a 
concentration of 2µ/ml after 9 and 12 hours of incubation. A lower pH-value increased the activity. The 
bacteria did not develop any resistance even after 10 passages grown at sub-inhibitory concentrations. The 
authors conclude that eugenol may prevent the growth of H. pylori. 
 
The antifungal acitivity of Syzygium aromaticum essential oil against Aspergillus section Flavi was 
evaluated in sterile maize grain. The effect of the essential oil added to maize grains on growth rate, lag 
phase, and aflatoxin B1 (AFB1) accumulation of Aspergillus section Flavi were evaluated at different 
water activity conditions (0,982; 0,955; and  0,90). The essential oil had an inhibitory effect on 
Aspergillus section Flavi growth rate; the efficacy depended mainly on the water activity and 
concentration. Clove essential oil showed a considerable inhibitory effect on the AFB1 accumulation. 
When the water activity was 0,982, the AFB1 inhibition percentage for all aflatoxigenic strains exceeded 
98% at all clove essential oil concentrations (Bluma & Etcheverry 2008).  
 
Dorman & Deans (2000) tested the antibacterial activity of the essential oil of S. aromaticum in 25 
bacteria The results suggest that the essential oil is equally effective against both Gram-positive and 
Gram-negative microorganisms. A different sensitivity of the bacteria tested was observed. 
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Eugenol significantly reduced the number of colony forming units sampled from the oral cavity or 
immunosuppressed rats treated for 8 days. Eugenol was used in a concentration of 24 mM (= double MIC) 
in agar solution. As positive control served Nystatin in a concentration of 58 µM (= tenfold MIC). 
Eugenol and nystatin gave similar results. Only few zones were occupied by hyphae, while under nystatin 
hyphae were found in the folds of the tongue mucosa (Chami et al 2004).  
There was a significant reduction of colony counts in a prophylactic and a treatment approach in case of 
vaginal candidiasis in an immunosuppressed rat model. The rats received 10 mg/kg/day Eugenol via an 
intravaginal route (Chami et al 2004).  
 
Lee et al (2007) evaluated the antifungal effect of eugenol against Microsporum gypseum. Eugenol was 
adjusted to 10% concentration with a base of Vaseline petroleum jelly and was applied topically to the 
infected skin lesions daily for 3 weeks. Eugenol was clinically active.  
 
Saini et al (2009) investigated the effect of orally administered essential oil on respiratory tract infections 
with Klebsiella pneumoniae in rats. The daily oral supplementation was 0.5 ml of a 1% w/v solution. The 
comparison of short term (15 days) and long term (30 days) treatment resulted in a significantly lower 
bacterial load in the lungs of mice fed clove oil for 30 days. The authors stated also a significant decrease 
of bacterial colonization already after 15 days.  
 
The composition and antifungal activity of clove essential oil were tested by Pinto et al (2009). MICs, 
determined according to Clinical and Laboratory Standards Institute protocols, and minimum fungicidal 
concentration were used to evaluate the antifungal activity of the clove oil and its main component, 
eugenol, against Candida, Aspergillus and dermatophyte clinical and American Type Culture Collection 
strains. The essential oil and eugenol showed inhibitory activity against all the tested strains. Propidium 
iodide rapidly penetrated the majority of the yeast cells when the cells were treated with concentrations 
just over the MICs. Therefore the fungicidal effect may result from extensive lesions of the cell 
membrane. 
Clove oil and eugenol also caused a considerable reduction in the quantity of ergosterol, a specific fungal 
cell membrane component. Germ tube formation by Candida albicans was completely or almost 
completely inhibited by the essential oil and eugenol concentrations below the MIC values. The authors 
conclude that the results indicate that clove oil and eugenol have considerable antifungal activity against 
clinically relevant fungi, including fluconazole-resistant strains. 
 
Antiviral effect: Eugeniin, which was found at a concentration of 0.1% in cloves, inhibited in vitro in FL-
cell cultures the replication of herpes simplex virus at a concentration of 10 µg/ml (Takechi M & Tanaka 
Y 1981). 
 
Kurokawa et al (1998) studied the effects of eugeniin on Herpes simplex virus -1. The effective 
concentration for 50% plaque reduction for HSV-1 on Vero cells was 5. 0 µg/ml, which is approximately 
14 fold lower than the 50% cytotoxic concentration. The viral DNA synthesis was found to be one of the 
major target sites of the inhibitory action. 
  
For eugenol no significant antiviral activity against herpes simplex virus type 1 was found (Astani et al 
2009).  
 
Spasmolytic effect: A saturated aqueous solution of clove oil was active in vitro on isolated organs against 
various spasmogenes: rat/duodenum/acetylcholine: 20 to 40% inhibition; rat/duodenum/bariumchlorid: 40 
to 60% inhibition; guinea-pig/ileum/histamine: >60% inhibition; rabbit/jejunum/nicotin: >60% inhibition. 
No further details on the methodology are available (Debelmas & Rochat 1967 cited in Blaschek et al 
2008). 
 
Clove oil antagonized in vitro the carbachol-induced spasm of the muscles of the trachea of the guinea-pig 
and the electrically stimulated contraction of the longitudinal muscles of the ileum of the guinea-pig. The 
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EC50 was 3,8 mg/ml (trachea; isoprenaline EC50 = 3,9 nmol/l) or 6,8 mg/ml (ileum; papaverine EC50 = 
3,7 µmol/l) (Reiter M & Brandt W 1985). 
 
Eugenol relaxes the rabbit thoracic aorta while suppressing the Ca2+ sensitivity and both the uptake and 
extrusion mechanisms for Ca2+ (Nishijima et al 1999). 
 
Effect on coagulation: Clove oil inhibited in vitro the platelet aggregation which was induced by 
arachidonic acid, epinephrine and collagen. The formation of thromboxane B2 induced by arachidonic 
acid was inhibited in intact and in lysed platelet preparations. The effect, which exceeds the in vitro effect 
of acetylsalicylic acid might be attributed to eugenol and eugenyl acetate. The combination of these 
compounds inhibits the platelet aggregation in a superadditive manner (Srivastava & Malhotra 1991, 
Srivastava 1993,   
Srivastava & Justesen 1987, Srivastava 1990 cited in Balschek et al 2008, Srivastava 1993).  
 
Effect on prostaglandinsynthesis: At in-vitro-preparations from the seed bubble of sheep, inhibits the 
additive of 37 µM clove oil (based on average molecular weight of 200) the prostaglandin synthesis from 
1-14C-arachidonic acid compared to a control without the essential oil by 84,1%. IC50 of eugenol 11,0 
µM, of indomethacin 1,2 µM (Wagner et al 1986).  
Eugenol and its derivatives are inhibitors of LOX-5 and COX-2 (Hübner 2008). 
 
Sedative effect: Wagner & Sprinkmeyer (1973) investigated the sedative effect of clove essential oil. Mice 
received 1 to 100 mg/kg KG p. o. The motility in the photocell cage was compared with the results of the 
day before (without treatment). The authors observed a not dose-dependent reduction of motility. 
 
Assessor’s comment: A statistical evaluation is lacking. The investigation is due to significant deficiencies 
not suitable for a detectable sedative effect.  
 
Antiprotozoal effects: Clove oil inactivated in vitro Trichomonas vaginalis in a dose-and time-depending 
manner. After addition of 4, 2, 1, 0,5 and 0,25 mg/ml to the culture medium no surviving Trichomonads 
were detectable after an incubation period of 5 min to 8 hours. Concentrations of 0,1 and 0,05 mg/ml were 
not effective. With eugenol comparable effects were achieved. With 4 – 0,05 mg/ml of the reference 
substance metronidazol the effect was achieved after 30 min to 2 h (Salem 1980 cited in Blaschek et al 
2008). 
 
Treatment of epimastigotes of Trypanosoma cruzi with different concentrations of clove essential oil 
resulted in a dose-dependent growth inhibition, with IC50/24 h of about 99,5 µg/ml; IC50/24 h values 
obtained after treatment of bloodstream trypomastigotes were about 57,5 µg/ml. The values obtained for 
epimastigotes treated with eugenol were 246 µg/ml, while treatment of bloodstream trypomastigotes 
resulted in IC50/24 h values of 76 µg/ml for eugenol (Santoro et al 2007). 
 
Effect as repellent: In study by Eamsobhana et al (2009) commercially produced essential oils of 13 plant 
species and ethanol (control) were tested for repellent activity against host-seeking chiggers of 
Leptotrombidium imphalum. Dilutions of each essential oil were prepared in absolute ethanol. Clove 
essential oil exhibited 100% repellent activity at 5% concentration. 
Eugenol as repellent (Hassanali et al 1990 cited in Blaschek et al 2008). 
 
Antimutagenic activity: Miyazawa & Hisama (2003) identified dehydrodieugenol and trans-coniferyl 
aldehyde as the antimutagenic compounds in clove. These compounds showed suppressive effects on umu 
gene expression of the SOS response in S. typhimurium TA1535/pSK10002 against furylfuramide, 
4NQO, and MNNG, which do not require liver-metabolizing enzymes, and AFB1 and Trp-P-1, which 
require liver-metabolizing enzymes and UV irradiation. Dehydrodieugenol had stronger suppressive 
potencies.  
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Anti-genotoxicity: Anti-genotoxic effects of eugenol were assessed in the mouse bone marrow 
micronucleus test by Abraham (2001). The test doses of eugenol were administered to mice by gavage 2 
and 20 h before exposure to the genotoxin. A pre-treatment with 50-500 mg / kg BW eugenol resulted in 
significant reductions with cyclophosphamide, procarbazine, methylnitronitrosoguanidine and urethane. 
The administration of eugenol alone did not exert genotoxicity. 
 
Cytotoxicity: An in-vitro study demonstrates cytotoxic properties of both the oil and eugenol, towards 
human fibroblasts and endothelial cells. Clove oil was found to be highly cytotoxic at concentrations as 
low as 0.03% (v/v) with up to 73% of this effect attributable to eugenol. ß-Caryophyllene did not exhibit 
any cytotoxic activity, indicating that other cytotoxic components may also exist within the essential oil. 
The viability of all cell types dropped by 60 – 90% when the concentration of the oil was increased from 
0.01% to 0.03% (Prashar et al 2006).  
High doses (0.05% clove oil; 2.50mM eugenol) of the essential oil and its components into culture media 
already markedly increased the percentage of both necrotic and apoptotic cells after 1 h (clove oil: 
18,04%; eugenol: 21,64%). The medium doses (0.01% clove oil; 0.52mM eugenol) did not cause 
significant damage to the Caco-2 population after 1 h culture when compared with control (Fabian et al 
2006). 
 
Use of eugenol in dentistry 
Eugenol can be part of temporary pulp fillings in dentistry. Eugenol is mixed with zinc oxide giving a 
paste which hardens quickly when coming into contact with saliva. This special application is not within 
the scope of a Community monograph and will therefore not be further discussed. 
 
Other effects:  
Hepatoprotective Effects: Eugenol may protect the liver from damage by certain chemicals, including iron 
overload. The mechanism may involve eugenol acting both as an antioxidant to prevent lipid peroxidation 
and by scavenging free radicals by conjugating with glutathione. In an animal study, eugenol reduced the 
hepatic injury caused by iron overload. Eugenol lowered liver lipid peroxidation by 38% and serum lipid 
peroxidation by 30% in iron-treated rats (Gruenwald et al 2004). 
Induction of Gluthation-S-Transferase by eugenol and caryophyllene (A&B) and caryophyllene oxide 
(A&B) (Patel et al 1977 cited in Blaschek et al 2008). 
 
Clove essential oil increased the total white blood cell count and enhanced the delayed-type 
hypersensitivity response in mice. Moreover, it restored cellular and humoral immune responses in 
cyclophosphamide-immunosuppressed mice in a dose-dependent manner. The immunostimulatory activity 
found in mice treated with clove essential oil is due to improvement in humor- and cell-mediated immune 
response mechanisms (Carrasco et al 2009).  
 
Eugenol attenuates the reduction of dopamin. Eugenol administration 3 days before and 7 more days 
following one intracerebroventricular injection of 6- hydroxydopamine prevented the reduction of striatal 
dopamine and its metabolites. This effect suggests it possible usefulness for the treatment of Morbus 
Parkinson (Kabuto et al 2007).  
 
Eugenol depressed cell respiration in homogenates of human dental pulp and in mouse fibroblast 
monolayers. The authors conclude that the irritant effect of zinc oxide eugenol when applied directly to 
soft tissue is due to the fact that concentrations of eugenol are achieved which are sufficient to inhibit 
respiration and thus kills cells (Hume 1984). 
 
Molluscicidal activity: Treatment with 20% and 60% of the 96 h LC50 of eugenol caused in the test 
animals of the snail Lymnaea acuminate significant inhibition of the alkaline phosphatase and 
acetylcholinesterase activities (Kumar et al 2009). 
 
Allen & Cornforth (2009) demonstrated the iron chelating ability of eugenol. In presence of iron, Type I 
antioxidants like eugenol had a significant prooxidant effect.  
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The aim of the study by Kahn et al (2009) was to evaluate quorum sensing (QS = mechanism by which 
bacterial population measures its cell density) inhibitory activity of plant essential oils using strains of 
Chromobacterium violaceum (CV12472 and CV026) and Pseudomonas aeroginosa (PAO1). Significant 
inhibition of pigment production was detected in clove oil with 19 and 17 mm zone of pigment inhibition 
against CV12472 and CV026 strains. Clove oil, at lower concentration (2µl) showed no activity, but at 
higher concentration (20 µl) antibacterial activity was observed along with anti-QS activity (zone of 
inhibiton 21 mm). Eugenol does not seem to be responsible for these effects. 
 
Eugenol fulfills all points of a narcotic for commercial fish. Clove oil is allowed as food additive and 
therefore an administration to food-producing animals is possible. The allowed daily intake for the United 
States is reported with 2.5 mg/kg (Oetinger 2003). 
 
Clove oil is active against the eggs and second-stage juveniles of the parasitic nematode Meloidogyne 
incognita (Meyer et al 2008). 
 
Mild hypertension has resulted in dogs after receiving 0,05 ml of eugenol (Gruenwald et al 2004). 
 
Overview of available pharmacokinetic data regarding the herbal substance(s), herbal 
preparation(s) and relevant constituents thereof 
 
No specific data are available on Caryophylli flos or Caryophylli floris aetheroleum. 
 
In case of systemic treatment an effect of phenolic compounds is only expected at higher doses because of 
a rapid metabolism (Wagner 2003). 
 
Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) 
and constituents thereof 
 
Toxicity of Caryophylli flos: 
 
Acute Toxicity:  
The acute toxicity of a decoction of clove was studied in 30 overnight fasted mice. Doses of 100-520 
mg/kg BW were administered intraperitoneally, larger doses of 500-5000 mg/kg BW by oral gavage. The 
animals were observed for respiratory, GIT, CNS symptoms, behavioural patterns and mortality. The only 
toxic manifestation was abdominal cramps. 
The LD50 was interpolated as 263 mg/kg (i. p.) and 2500 mg/kg (oral) (Agbaje et al 2009). 
 
Tajuddin et al (2003) studied the acute toxicity of an ethanolic extract (DER app. 10:1, ethanol 50%). 6 
mice received 500 mg/kg extract p.o. No signs of mortality or gross behavioural changes were observed. 
 
Subchronic toxicity:  
Swiss albino mice received for 10, 20 and 30 days 0.5%, 1% and 2% w/w clove powder in the diet. 
Enhanced Glutathion-S-transferase, cytochrome b5 and sulphydryl enzymes levels were observed in all 
the treatment groups, excepting those maintained on a 0.5% diet for 10 days. A significant reduction in 
CYP-450 and malondialdehyde levels was observed in all groups at 30 days duration (Kumari 1991). 
. 
After 90 days of administration of a decoction of clove at doses of 300 mg/kg and 700 mg/kg in rats 
significant alterations in liver enzymes and haematological parameters were observed. Even in the lower 
dose histopathological modifications could be found in body organs. The authors conclude that a 
prolonged use of decoctions of clove should be avoided (Agbaje et al 2009). 
 
Mutagenicity:  
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The dry residue of aqueous and methanolic extracts showed mutagenic effects in the rec assay in Bacillus 
subtilis mutagenic. The mutagenic activity in the Ames test on Salmonella typhimurium TA98 and TA100 
was not assessable due to the antimicrobial action (Morimoto et al 1982). 
 
An anti-microbial effect from drug quantity of 50 mg / plate in another work, also makes the assessment 
of the mutagenicity of extracts of clove on TA98 and TA100 impossible  
(Opdyke 1975 cited in Blaschek et al 2008). 
 
After administration of a decoction (1:100) of cloves to Drosophila no genotoxic effects were observed 
(Schulz & Herrmann 1980 cited in Blaschek et al 2008).  
 
An in vivo bone marrow micronucleus assay demonstrated that the administration of 0.5% and 2% of 
clove in the diet of mice for 10 days neither significantly induced micronuclei nor could effectively 
modulate the 7, 12-dimethylbenz[a]anthracene genotoxicity in mice (Kumari 1991). 
 
Reproduction toxicity:  
Data from Caryophylli flos are not available. However, the herbal substance contains oleanolic acid. For 
oleanolic acid isolated from Syzygium jambos flowers a possible anti-estrogenic effect is docuemented 
(Rajasekaran et al 1988).  
Rats received orally 15 mg /kg BW or 30 mg/kg BW olenolic acid daily over a period of 60 days. This 
dosage is equivalent to app. 0.8 to 3 g clove per kg BW. A histological examination of the testes showed a 
dose-dependent reduction in the number of spermatides and spermatocytes of 2.69 (control) to 1.73 and 
0.93. The number of fertilized females was reduced from 20/20 (control) to 7 / 20 or 2 / 20. The number of 
implants also decreased from 8.80 to 5.43 and 2.55. 
 
Mishra & Singh (2008) investigated a hexane extract in doses of 15-60 mg/kg BW per os in mice over 35 
days. The treatment did not induce systemic toxicity at the doses tested. AT 15 mg/kg BW the activities of 
testicular enzymes and serum levels of testosterone were increased. At doses of 30 mg and 60 mg/kg BW 
these parameters were inhibited. Additionally non-uniform degenerative changes in the seminiferous 
tubules associated with a decrease in daily sperm production were observed. 
 
 
Toxicity of Caryophylli floris aetheroleum and constituents thereof:  
 
Toxicity:   
Essemtial oil (Blaschek et al 2008): 
Rat, p.o., 1.8 – 3.72 g/kg 
Rabbit, cutaneous application, 5 g/kg 
 
Eugenol (Blaschek et al 2008):  
Rat: p.o. LD50 2.68 g/kg; i.p. LD50 800 mg/kg 
Mouse: p.o. LD50 3 g/kg; i.p. LD50 500 mg/kg 
 
Acute Toxicity:  
After oral administration of 5000 mg/kg of the essential oil in rats, all animals died within 24 h. The 
autopsy showed bleeding in the stomach and intestines, and pleural effusion (Blaschek et al 2008). 
 
On the isolated rabbit lung, the addition of 1.0 mM eugenol resulted in edema, as measured by the 
increase in lung weight and wet/dry weight of the lung. The addition of catalase (1000 U/mL) or 
dimethylthiourea (30 mM) decreased the response. Dimethylurea, superoxide dismutase or heat 
inactivated catalase had no influence (McDonald & Heffner 1991). 
 
A p. o. without a single dose of 140 mg / animal resulted in rats within a short time to death. Undiluted 
clove applied on the dorsal skin of hairless mice did not cause irritation. On intact or shaved rabbit skin 
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clove essential oil acted under occlusive conditions as a weak irritant. Phototoxic effects were not 
observed with undiluted clove oil on hairless mice and pigs (Opdyke 1975 cited in Blaschek et al 2008).  
 
Chronic toxicity: Clove essential oil in oral dosages of 35 or 70 mg per animal (rat) over 8 weeks of rats 
were tolerated without signs of toxicity. Higher doses led to inactivity and weight loss. 105 mg / animal p. 
o. daily for 2 to 3 week led to serious liver and kidney damage and death of the animals (Opdyke 1975 
cited in Blaschek et al 2008).  
 
Mutagenicity, Genotoxicity:  
No signs of a mutagenic effect could be observed in the in vitro chromosomal aberration test in fibroblasts 
from Chinese hamsters at concentrations up to 0.04 mg / mL of clove oil (Ishidate et al 1984).  
 
No evidence of a mutagenic activity could be detected in clove oil (10 to 250 µl) in vitro in Salmonella 
typhimurium TA1530 and G46 without metabolic activation (Litton 1975). 
 
The National Toxicology Program (NTP) performed a mutagenic study on eugenol.. The study finished 
1980. Outcome:  
AMES-Test (TA1535, TA100, TA98, TA1537 strains with mebabolic activation): negative; Mouse 
lymphoma: positive, Sister chromatide exchange: positive; Chromosome aberrations: positive; 
Micronucleus: negative; Drosophila: negative; in vivo sister chromatid exchange: positive; in vivo 
chromosome aberrations: equivocal. (NTP 1980)  
 
Eugenol was tested for mutagenic activity in the AMES-test using S. typhimurium TA 1535, TA 100 and 
TA 98. For TA 100 and TA 98 strains no mutagenicity was detected, but in case of TA 1535 strain dose-
dependent mutagenicity was observed (Swanson et al 1979). 
 
Eugenol induces chromosome aberrations in Chinese hamster lung cells and exerts a cell-transforming 
activity in Syrian hamster embryo cells (Hikiba et al 2005).  
 
An in vitro chromosome aberration test in fibroblasts of Chinese Hamsters revealed no signs of 
mutagenicity at concentrations up to 0.04 mg/ml of clove oil (Ishidate et al 1984). 
 
Maralhas et al (2006) demonstrated that eugenol induces chromosome aberrations, including exchanges, 
in V79 cells, in particular in the presence of rat liver S9 mix, which suggests biotransformation to reactive 
metabolites. Eugenol induced chromosomal aberrations significantly (3.5% aberrant cells) at 2500 µM, 
demonstrating cytotoxicity in higher doses. S9 increases the number of aberrant cells to 15% with a high 
frequency of chromatid exchanges. Additionally an increase in endoreduplicated cells was observed. The 
authors suggest that eugenol exhibits topoisomerase II inhibiting activity.  
 
Eugenol was also tested by Ellahuene et al (1994) in the mouse bone marrow micronucelus assay. Single 
doses of 400 and 600 mg/kg eugenol induced a statistically significant increase in the induction of 
micronucleus-polychromatic erythrocytes compared to the negative control (Ellahuene MF, Pérez-Alzola 
LP, Orellana-Valdebenito M, Muňoz C & Lafuente-Indo N 1994). 
 
Reproductive and developmental toxicity:  
Domaracky et al (2007) investigated the effects of clove essential oil on the growth and development of 
mouse preimplantation embryos in vivo. The animals received 0.25% essential oil in the commercial diet 
(=375 mg/kg per day). Treatment with clove essential oil induced a significantly higher percentage of 
dead cells compared to the control group. 
 
Female CD-1 mice were given from day 6 to day 15 of gestation p. o. 2.2 to 215.0 mg / kg BW of clove 
oil daily. The foetuses were obtained on day 17th. The use of clove oil had no apparent toxic effect on the 
implantation and survival of the mother and foetus. The number of malformations of the soft tissues and 
the skeletal system was not different from that in the control group spontaneously occurring. Same results 
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were obtained in female Wistar rats following daily p. o. administration of 2.8 to 280 mg / kg BW (6 to 15 
of gestation, foetuses at day 20), to golden hamsters after p. o. 1.8 to 177.0 mg / kg BW (6 to 10 of 
gestation, foetuses at day 14) and in rabbits by 1.72 to 172.0 mg / kg BW (6 to 18 of gestation, foetuses at 
day 29) achieved (Blaschek et al 2008). 
 
 
 
 
Carcinogenicity:  
The carcinogenicity of eugenol evaluated within the US National Toxicology Program. A negative 
outcome for F344 rats of either sex was found. However, equivocal results were observed in B6C3F1 
mice (NTP 1983).  
 
Local toxicity: 
Undiluted eugenol (no data on amount of eugenol) was applied to a circumscribed area 3 mm in diameter 
of rat labial mucosa for one minute. Reaction periods of 15 minutes, 1, 2, 4 and 6 hours were then 
permitted. Using routine histological procedures for processing the experimental tissues, it was observed 
that eugenol caused denaturation of cytoplasmatic proteins and loss of staining capacity of epithelium, loss 
of cell boundaries, swelling and cell necrosis. In addition, vesicle formation, oedema in the corium, and 
striated muscle dissolution were observed (Kozam & Mantell 1978).  
 
Overall conclusions on non-clinical data 
The published data referred to the indications and preparations is very limited, but on the basis of existing 
data the pharmacological activities support the traditional use of Caryophylli flos and Caryophylli 
aetheroleum and preparations thereof in the proposed indication: For the temporary relief of toothache due 
to a dental cavity and for the treatment of minor inflammations of the symptomatic treatment of minor 
inflammations in the mouth or the throat. 
 
Since the efficacy of traditional herbal medicinal products is only plausible the safety must be guaranteed. 
In the case of Caryophylli aetheroleum the main component eugenol gives reason for safety concerns. 
Natural compounds with a similar chemical structure like safrole and methyleugenol are known as 
genotoxic carcinogens. Available data regarding genotoxicity of eugenol are inconsistent and equivocal. 
The scientific discussion on risks associated with the oromucosal or oral use of clove or clove essential oil 
is still at the beginning. A final conclusion cannot be drawn at the moment. 
In the case that the possible risks overbalance the plausible efficacy the further development of a 
monograph on clove essential oil has to be cancelled. 
The safety concerns do not allow the establishment of a Community List Entry. 
 
3.2.4. Clinical Data 
 
 
Clinical Pharmacology 
 
Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including 
data on relevant constituents 
 
Eugenol caused a ‘comfortable feeling’ in the 13 female subjects. Alpha 1 of EEG significantly decreased 
after inhalation. Suppression of alpha 1 indicates the neural activity around the brain regions. There is a 
possible positive correlation between alpha 1 activity and subjective evaluation (Masago et al 2000). 
 
Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data 
on relevant constituents 
No data available for the entire essential oil. 
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Eugenol: 
The metabolism of eugenol was investigated in male and female healthy volunteers by Fischer et al 
(1990).  
Eugenol was rapidly absorbed and metabolized after oral administration and was almost completely 
excreted in the urine within 24 h. Unmetabolized eugenol was found in the urine less than 0.1% of the 
dose. The urine contained conjugates of eugenol and of nine metabolites they were identified as: eugenol, 
4-hydroxy-3-methoxyphenyl-propane, cis- and trans-isoeugenol, 3-(4-hydroxy-3-methoxyphenyl)-
propylene-1, 2-oxide, 3-(4-hydroxy-3-methoxyphenyl)-propane-1,2-diol, and 3-(4-hydroxy-3-
methoxyphenyl)-propionic acid. 95% of the dose was recovered in the urine, most of which (greater than 
99%) consisted of phenolic conjugates; 50% of the conjugated metabolites were eugenol-glucuronide and 
sulphate.  
 
Clinical Efficacy  
 
Dose response studies 
 
There is no data available. 
 
Clinical studies (case studies and clinical trials) 
 
Clinical studies in the proposed indication: 
There is no data available. 
 
Other clinical studies: 
 
Central effects: The influence of clove oil on psychometric parameters such as mood, affective reaction, 
memory and cognitive abilities in 21 male and 51 female probands was studied in a cross-over trial. The 
concentration in the room air conditioning was corresponding to 0.0057 – 0.0167 g/m3. No differences in 
the examined parameters could be observed (Wagner & Sprinkmeyer 1973). 
 
Clinical studies in special populations (e.g. elderly and children) 
 
There is no data available. 
 
Overall conclusions on clinical pharmacology and efficacy 
 
No clinical data are available for Caryophylli flos and Caryophylli aetheroleum in order to support well-
established use. 
 
Therefore the medicinal use has to be regarded as traditional. 
 
 
 
3.2.5. Clinical Safety/Pharmacovigilance 
 
Overview of toxicological/safety data from clinical trials in humans 
 
There is no data available. 
 
Patient exposure 
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There is no data available. 
 
Adverse events  
 
Skin and mucosal irritations: 
In concentrated form, oil of clove may be irritating to mucosal tissues (Gruenwald et al 2004). 
In contrast to this Anton et al (2001) report that there is no skin irritation (undiluted oil) on hairless mice.  
Under occlusion clove (undiluted oil) was moderately irritating in rabbits. 
With direct application to the exposed pulp, pulp necrosis and inflammation appeared. (Reichl et al 2007) 
 
Allergic effects:  
In patients sensitized to Peru balsam a hexane extract of clove resulted in concentrations higher than 
0.12% in petrolatum in local reactions. In ac concentration of 1% in petrolatum in two of four patients at a 
moderate reaction was observed, the other two an intense reaction (large, infiltrated, dark spots with 
numerous vesicles) occurred (Bouhlal et al 1989 cited in Blaschek et al 2008). 
 
In an epicutaneous test with clove powder (on filter paper moistened with water) out of 78 patients with 
allergy against Peru balsam reacted 36 positive. In a control group of 156 probands lacking Peru balsam 
allergy nobody responded positively (Niinimäki 1984). 
 
A 22 years old patient with eczema on the hands reacted to a p. o. stress test with 2 times 100 mg clove 
powder in gelatine capsules with blisters on palms and fingers (Niinimäki 1984). 
 
Clove cigarettes have been reported to cause acute respiratory problems in humans that rapidly progress to 
hemorrhagic pulmonary oedema or pneumonia (Gruenwald et al 2004). 
 
In a patch test study a 10% ethanol extract of Caryophylli flos was investigated among other herbal 
preparations used in the Traditional Chinese Medicine. Out of 30 patients 8 reacted positively to clove 
extract (Chen et al 2003). 
 
A root canal filling with eugenol cement resulted in a patient with a generalized urticaria. In the skin test, 
the patient responded positively to Perubalsam and cloves. A distributed oral provocation test with 0.1 to 
0.5 mL of eugenol, in water, resulted in urticaria, which persisted for several weeks (Grade & Martens 
1989). 
 
Clove oil, 20% incorporated in petrolatum, produced in 2 of 25 healthy subjects an erythema. In 
concentrations of 2% and 0.2% in petrolatum no reaction were observed (Opdyke 1975 cited in Blaschek 
et al 2008). 
 
 
 
Systemic effects (case report): 
When trying to administer clove essential onto an aching tooth a 24 year old woman disposed accidentally 
on the oil on the upper lip and cheek. Although she tried to remove the essential oil a sensation of burning 
and inflammation occurred, which disappeared within a few hours. Subsequently a local anaesthesia and 
reduced sweat production in the affected areas was observed. The medical examination after 11 months 
revealed a dry, slightly erythematous skin with reduced pressure sensitivity. During the following 9 
months the situation remained unchanged (Isaacs 1983). 
Contraindications: 
The medicinal use of clove essential oil should be contraindicated in cases of hypersensitivity to clove 
essential oil as well hypersensitivity to Peru balsam. 
 
Serous adverse events and deaths 
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A 17-year-old male high-school student died of rapidly progressive inflammatory lung disease that 
developed hours after smoking a clove cigarette. The student was recovering from a lower respiratory 
infection at the time. The California Department of Health Service and Centers for Disease Control 
collected 110 cases of clove cigarette toxicity by 1984, two of which were fatal. Clove cigarettes have 
been reported to cause acute respiratory problems in humans that rapidly progress to hemorrhagic 
pulmonary edema or pneumonia (Gruenwald et al 2004). 
 
During 1984 and 1985, the Centers for Disease Control received 11 case reports of clove cigarette 
smoking-associated acute respiratory system injury in adolescents and young adults; two deaths were also 
reported. The typical clove cigarette smoker inhales approximately 7 mg of eugenol per clove cigarette. 
The reported respiratory adverse effects included haemoptysis, bronchospasms, hemorrhagic and non-
hemorrhagic pulmonary oedema, pleural effusion, respiratory insufficiency, respiratory infection, and 
aspiration of foreign material. The hazards of chronic long-term use of clove cigarettes are unknown 
because they have not been studied systematically during a long period of time (Priutt et al 1991). 
Clove affects cellular respiration as well. Eugenol inhibits cytochrome oxidase, thus poisoning the 
mitochondria (Gruenwald et al 2004). 
 
Laboratory findings 
 
There is no data available. 
 
Safety in special populations and situations 
 
Intrinsic (including elderly and children) / extrinsic factros 
None known. 
Drug interactions 
The antiplatelet effect of clove oil may increase the risk of bleeding if taken with these medications. Clove 
may result in a false increase in phenytoin levels (Gruenwald et al 2004). 
 
Assessor’s comment: The proposed route of administration is the oromucosal use; the duration of use is 
limited. Therefore these mentioned theoretical drug interactions are not relevant for the traditional use of 
clove oil for the short term treatment of tooth ache or as an antiseptic mouthwash. 
Use in pregnancy and lactation 
No data are availabl. In the absence of sufficient data, the use during pregnancy and lactation is not 
recommended. 
 
Overdose 
Case reports:  
A 7-month-old boy received 1 teaspoon of clove oil. The dose corresponds to about 500 mg / kg eugenol. 
On admission to hospital was an attenuation of the CNS (awake, but without a direct response to 
environment), leukocytosis, proteinuria, and ketonuria were observed. The also observed metabolic 
acidosis was attributed to the already existing diarrhoea. 3 h after ingestion, gastric lavage was performed 
with the addition of activated carbon. An endoscopy the next morning showed no evidence of mucosal 
damage in the stomach or oesophagus. After 48 h acidosis and leukocytosis were no longer detectable. 
The patient recovered completely and was released from hospital after 4 days (Lane et al 1991).  
 
A 2 year old boy drank 5 to 10 mL of clove oil. After 1 hour no only mild drowsiness was observed. 
Within the next 3 hours, a drastic deterioration occurred with deep coma and severe acidosis. 8.5 hours 
after the ingestion generalized cramps occurred which were treated with diazepam. The patient had an 
unrecordable blood glucose level which was treated with intravenous dextrose. 24 hours after ingestion, 
the patient was unconscious. A severely impaired liver function and disseminated intravascular 
coagulopathy (therapy with plasma, heparin, antithrombin III, protein C, factor VII) was observed. The 
liver function deteriorated further in the following days. During the 5th day the patient awoke and on day 
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6 he was fully conscious. From this timepoint the symptoms gradually disappeared, the patient fully 
recovered (Hartnoll et al 1993).  
 
A very similar case – ingestion of about 10 mL of clove oil by a 2-year boy resulting in convulsions, 
unconsciousness and severe coagulation - is described in Blaschek et al (2008).  
 
Drug abuse 
None reported. 
Withdrawal and rebound 
None reported. 
Effects on ability to drive or operate machinery or impairment of mental ability 
None reported. 
 
Overall conclusions on clinical safety 
Clove essential oil acts in high concentrations as local irritant, allergic reactions may also be possible. 
However, when applied in diluted form no reports on severe adverse events are published. Clinical safety 
when applied correctly can be established. 
 
3.2.6. Overall Conclusions 
The positive effects of Caryophylli flos, Caryophylli floris aetheroleum and preparations 
thereof on inflammatory changes of the oral and pharyngeal mucosa, or in dentistry, for 
topical anaesthesia have long been recognised empirically. The use is made plausible by 
pharmacological data. There is al lack of controlled clinical studies, using herbal 
preparations, containing the herbal substance Caryophylli flos, Caryophylli floris 
aetheroleum. 
In conclusion, Caryopyhlli flos, Caryophylli floris aetheroleum and its preparations can be 
regarded as traditional herbal medicinal products.  
The potential genotoxicity of eugenol, the major constituent of the essential oil, has to be 
further assessed. The structural similarity to other known genotoxic carcinogens is the reason 
for these safety concerns. 
Therefore a final benefit-risk assessment is not possible based on the current data. Experts in 
toxicology have to be involved in the further development of the Community monograph on 
Caryophylli aetheroleum. 
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4. DISCUSSION 
 
The medicinal use of Tormentillae rhizoma can be traced in literature back to the 15th century. 
In fact tormentil is an old medicinal herb with a long history of traditional use as herbal tea and in 
liquid and dry extracts. Therefore for Tormentillae rhizoma a period of medicinal use of at least 
30 years (15 years in and 15 years outside the EU) as requested by Directive 2001/83, article 16c 
1 (c) or 2004/24 EC for qualification as a traditional herbal medicinal product is easily fulfilled. 
Its traditional use for acute unspecified diarrhoea and inflammations in the mouth or throat is 
plausible due to the content on tannins and the known pharmacological properties of tannins. 
 
In some old handbooks further traditional indications were mentioned like haemostasis, 
prosthetic pressure points, frostbites, burnings, haemorrhoids and poorly healing wounds. 
 
The literature search and the evaluation of the scientific information for the establishment of an 
assessment report and a draft monograph for the European Medicines Agency EMA were 
designed under several aspects. 
 
Every indication has to be connected with a well defined herbal preparation and a well defined 
posology. On account of this scientific literature data bases were sought for clinical data. 
Formerly and up-to-date pharmaceutical literature was evaluated particularly with regard to 
traditional indications and preparations. Supplemental data on authorized products were collected 
within the EU (regulatory status overview).  
 
In the draft monograph five herbal preparations are specified which were used traditionally: The 
comminuted herbal substance, two different tinctures, a liquid and a dry extract are described.  
 
Tormentil is in medicinal use in products as single active ingredient, in combination products as 
well as in food supplements within the member states like shown in the regulatory status 
overview. 
 
The toxicological data for Tormentillae rhizoma is limited, but with respect to the existing data, 
there are no safety concerns for the use as traditional herbal medicinal product. The use in 
children and adolescents under 18 years of age is documented. Therefore the use should be 
restricted to adults. Safety during pregnancy and lactation has not been established. 
 
The available non-clinical data on tannins allowed the elaboration of an extensive overview on 
pharmacological topics. Antiviral, astringent, antimicrobial, anti-inflammatory, 
immunostimulatory, interferon inducing, molluscicide, hypoglycaemic, antioxidant, and 
antitumor effects were shown in different studies. There was no information found concerning 
clinical pharmacodynamics and only one clinical study relating to pharmacokinetic data is 
published. The efficacy is not confirmed by clinical data. Consequently the criteria for well-
established use are not fulfilled. 
 
Since the benefit-risk evaluation is clearly positive the traditional use of herbal preparations of 
Tormentillae rhizoma can be recommended in a community monograph.  
The medicinal use of Caryophylli flos and Caryophylli aetheroleum can be traced in literature 
back to the 13th century. In fact Caryophylli flos and its essential oil have been in therapeutic use 
for many decades. Unfortunately no medicinal products containing Caryophylli flos as the only 
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active ingredient could be identified in the EU member states. Therefore no monograph on clove 
can be established. The essential oil is in medicinal use in several products in the United 
Kingdom for decades. Therefore concerning Caryophylli aetheroleum a period of at least 30 
years in medicinal use as requested by Directive 2004/24 EC for qualification as a traditional 
herbal medicinal product is fulfilled. 
Caryophylli flos is traditionally used primarily as a spice. Traditional literature mentions the use 
in indications like inflammatory changes of the oral and pharyngeal mucosa, in dentistry for local 
anaesthesia, for dyspeptic complaints, flatulence and diarrhoea.  
Caryophylli floris aetheroleum is traditionally used for external or local applications for the 
treatment of toothache, and minor infections of the mouth and skin, dressing of minor wounds, 
sore throats and coughs associated with common cold. Caryophylli floris aetheroleum or eugenol 
alone is mixed with zinc oxide as temporary filling material in dentistry. Some authors mention 
also myalgia, rheumatic complaints, insect bites, flatulent colic, and nausea as traditional 
indications. The high content of eugenol makes the medicinal use in the proposed indication 
plausible. 
Since the efficacy of traditional herbal medicinal products is only plausible the safety must be 
guaranteed. In the case of Caryophylli aetheroleum the main component eugenol gives reason for 
safety concerns. Natural compounds with a similar chemical structure like safrole and 
methyleugenol are known as genotoxic carcinogens. Available data regarding genotoxicity of 
eugenol are inconsistent and equivocal. Therefore a comprehensive assessment of the risk 
associated with the use of Caryophylli aetheroleum in traditional herbal medicinal products has to 
be performed. In the worst case, only an assessment report will be published. 
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5. ABSTRACT 
 
The goal of my diploma thesis was the development of first drafts of EU-community monographs 
and assessment reports Potentilla erecta L., rhizoma and Syzygium aromaticum L., flos and 
aetheroleum. In these documents the scientific knowledge as well as the concrete use in the EU 
member states should be compiled according to ‘well-established use’ and ‘traditional use’ as 
defined by the EU legislation. The documents were prepared in accordance with the guidelines 
and templates of the European Medicines Agency (EMA). 
 
Literature search took place fom August 2009 to January 2010. Handbooks of pharmacy and 
phytotherapy were screened in the library of Pharmacy and Nutritional Sciences and the main 
library of the University of Vienna as well as in the Library of the Medical University of Vienna. 
Articles from journals were searched in several internet databases, above all PubMed, relevant 
articles were obtained in full text.  
Additionally data on authorised products containing tormentil or clove were collected.  
The assessment of the literature comprises topics such as constituents, pharmacology, 
pharmacokinetics, preclinical safety data, data on clinical efficacy, side effects, and interactions. 
 
There are no sufficient clinical data published, therefore tormentil and clove essential oil are 
restricted to traditional use only. 
 
There is long-documented traditional use of tormentil. Several herbal preparations exist in this 
context. The comminuted drug, two different tinctures prepared with ethanol-water mixtures, a 
liquid and a dry extract are listed in the monograph. The proposed preparations are indicated for 
mild diarrhoea and inflammation in the mouth and throat. The monograph, assessment report and 
list of references as presented were adopted after two rounds of discussions by the Committee on 
Herbal Medicinal Products of the EMA for public consultation. 
 
No data could be retrieved on medicinal products containing Caryophylli flos authorised in the 
EU. Therefore no monograph for this herbal substance will be proposed. The essential however is 
in medicinal use since at least 30 years; the indications ‘symptomatic treatment of toothache’ and 
‘minor infections in the mouth’ are plausible due to the published pharmacological properties. 
Before drafting a community monograph the potential genotoxicity of eugenol, the major 
constituent of the essential oil, has to be assessed. The structural similarity to other known 
genotoxic carcinogens is the reason for these safety concerns. The documents as presented in the 
diploma thesis are due to this ongoing discussion on safety still in the stage before the first 
discussion at the Committee on Herbal Medicinal Products of the EMA. 
 
The documents developed in this diploma thesis provide the basis for a further harmonisation 
within the European Union regarding traditional herbal medicinal products containing tormentil 
or clove essential oil. 
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5.1. ZUSAMMENFASSUNG 
 
Das Ziel meiner Diplomarbeit war die Entwicklung erster Entwürfe von EU-
Gemeinschaftsmonographien und Abschlussberichten von Potentilla erecta L., rhizoma und 
Syzygium aromaticum L., flos und aetheroleum. In diesen Dokumenten soll das 
wissenschaftliche Wissen wie auch die konkrete Verwendung in den EU Mitgliedsstaaten unter 
Berücksichtigung des ‘well-established use‘ und ‘traditional use‘, wie es in der EU Gesetzgebung 
definiert wird,  zusammengetragen werden. Die Dokumente wurden nach den Richtlinien und 
Vorlagen der EMA (European Medicines Agency) erstellt.  
 
Meine Literaturrecherche erstreckte sich von August 2009 bis Jänner 2010. Handbücher der 
Pharmazie und Phytotherapie wurden in der Bibliothek für Pharmazie und 
Ernährungswissenschaften und der Hauptbibliothek der Universität Wien, wie auch in der 
Bibliothek der Medizinischen Universität Wien durchgesehen. Zeitschriftenartikel wurden in 
einigen Internetdatenbanken gesucht, allen voran Pubmed, relevante Artikel wurden in Volltext 
erworben. 
Zusätzlich wurden Daten von autorisierten Produkten, welche Blutwurz oder ätherisches 
Nelkenöl enthalten, gesammelt. Die Beurteilung der Literatur umfasst Themen wie Inhaltsstoffe, 
Pharmakologie, Pharmakokinetik, Daten der präklinischen Sicherheit, Daten der klinischen 
Wirksamkeit, Nebenwirkungen und Interaktionen. 
 
Veröffentlichte klinische Daten sind nicht ausreichend, deshalb sind Blutwurz und ätherisches 
Nelkenöl auf die traditionelle Anwendung beschränkt. 
 
Für Blutwurz gibt es eine lang dokumentierte traditonelle Anwendung. Hier gibt es einige 
pflanzliche Zubereitungen. Die zerkleinerte Droge, zwei Tinkturen mit Ethanol-Wasser 
Mischungen, einen Flüssig- und einen Trockenextrakt findet man in der Monographie aufgelistet. 
Die vorgeschlagenen Zubereitungen sind bei mildem Durchfall und Entzündungen im Mund- und 
Rachenraum indiziert. Die präsentierte Monographie, der Abschlussbericht und die Liste der 
Referenzen wurden nach zwei Diskussionsrunden des ‘Committee on  Herbal Medicinal 
Products‘ der EMA für die öffentliche Konsultation aufgenommen. 
 
Es konnten keine Daten in Bezug auf medizinische Produkte, welche autorisiertes Caryophylli 
flos enthalten, erfasst werden. Deshalb wird für diese Pflanze vermutlich keine Monographie 
vorgeschlagen werden. Jedoch ist das ätherische Öl seit mehr als 30 Jahren in medizinischem 
Gebrauch; die Indikationen ‘symptomatische Behandlung von Zahnschmerzen‘ und 
‘geringfügige Infektionen der Mundhöhle‘ sind plausibel aufgrund der publizierten 
pharmakologischen Eigenschaften. 
Vor dem Entwerfen einer gemeinschaftlichen Monographie muss die potentielle Genotoxizität 
von Eugenol, dem Hauptbestandteil des ätherischen Öles, abgeschätzt werden. Die strukturelle 
Ähnlichkeit zu anderen bekannten genotoxischen Karzinogenen ist der Grund für die 
Sicherheitsbedenken. Die in der Diplomarbeit präsentierten Dokumente sind aufgrund der 
laufenden Diskussion hinsichtlich der Sicherheit noch einen Schritt von der ersten Diskussion des 
‘Committee on Herbal Medicinal Products‘ der EMA entfernt. 
 
Die in dieser Diplomarbeit entwickelten Dokumente liefern die Basis für eine weitere 
Harmonisierung innerhalb der Europäischen Union betreffend traditonelle pflanzliche 
medizinische Produkte, welche Blutwurz oder ätherisches Nelkenöl enthalten.  
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